Still Living Better through Chemistry: An Update on Caloric Restriction and Caloric Restriction Mimetics as Tools to Promote Health and Lifespan

Carla Almendáriz-Palacios 1✉, Darrell D. Mousseau 2, Christopher H. Eskiw 1,3 and Zoe E. Gillespie 3,✉

1 Department of Food and Bioproduct Sciences, University of Saskatchewan, Saskatoon, SK S7N 4A8, Canada; c.almendariz@usask.ca (C.A.-P.); c.eskiw@usask.ca (C.H.E.)
2 Cell Signalling Laboratory, Department of Psychiatry, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; darrell.mousseau@usask.ca
3 Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada
* Correspondence: zoe.gillespie@usask.ca; Tel.: +1-306-966-2454

Received: 7 November 2020; Accepted: 30 November 2020; Published: 3 December 2020

Abstract: Caloric restriction (CR), the reduction of caloric intake without inducing malnutrition, is the most reproducible method of extending health and lifespan across numerous organisms, including humans. However, with nearly one-third of the world’s population overweight, it is obvious that caloric restriction approaches are difficult for individuals to achieve. Therefore, identifying compounds that mimic CR is desirable to promote longer, healthier lifespans without the rigors of restricting diet. Many compounds, such as rapamycin (and its derivatives), metformin, or other naturally occurring products in our diets (nutraceuticals), induce CR-like states in laboratory models. An alternative to CR is the removal of specific elements (such as individual amino acids) from the diet. Despite our increasing knowledge of the multitude of CR approaches and CR mimetics, the extent to which these strategies overlap mechanistically remains unclear. Here we provide an update of CR and CR mimetic research, summarizing mechanisms by which these strategies influence genome function required to treat age-related pathologies and identify the molecular fountain of youth.

Keywords: caloric restriction; caloric restriction mimetics; amino acid restriction; lifespan; healthspan; mammalian target of rapamycin (mTOR); general control nonderepressible 2 (GCN2)

1. Introduction

Aging is an inevitable process experienced by all life on this planet. In humans (and numerous other species), aging comes with a battery of age-linked pathologies, including type 2 diabetes (T2D), cardiovascular disease (CVD), atherosclerosis, osteoarthritis, neurodegenerative diseases (ND), and cancer [1–4]. These pathologies are often the combination of nature and nurture; genetics play an important role, but environmental conditions (including exercise and diet) also have a significant impact on the rate at which individuals acquire disease and age. Excessive calorie intake increases the risk of many of the aforementioned age-linked pathologies, deleteriously promoting chronic inflammation and signaling insensitivities. Does aging have to be fraught with deteriorating health and increasingly poor quality of life until death? Or could healthy aging be feasible? Those that exercise and have a moderate diet are already shown to be at lower risk of numerous diseases, but could this effect be enhanced to promote longer, healthier lives? Addressing this question could have a
tremendous societal impact, decreasing the socioeconomic burden of an aging population and, as a result, is an intensively researched area of biology.

A key area of research for maintaining longer, healthier lives is caloric restriction (CR). CR is the reduction of nutritional intake to 60–80% ad libitum without inducing malnutrition or starvation. This approach has been successful and reproducible across laboratory-model organisms in extending lifespan (from yeast to nonhuman primates) [5–9]. Short-term trials of CR in humans have also proven effective in preventing and improving the treatment outcomes of age-linked pathologies such as cancer [10,11]. Despite the promise of CR, this regime is unlikely to be achieved, particularly as large percentages of individuals already struggle with obesity and thus moderating their diets (World Health Organization, 2020). Therefore, the question is: could alternative dietary regimes that may not require decreased food consumption achieve the same beneficial effects as CR? Or is there a pharmacological mimic of CR, a “magic pill,” that will alter how the body senses energy inputs and reproduces a CR-like state?

Amino acid restriction (AAR) is a potential CR alternative, with current work focusing on the efficacy of total AAR or the restriction of specific amino acids in promoting health and lifespan [12,13]. Similarly, the immunosuppressant rapamycin [14] (and the structurally related family of compounds called rapalogs [15]), the polyphenol resveratrol (found in the skin of red fruits, such as grapes) [16,17], and the T2D treatment metformin [18,19] have been examined for their ability to reproduce CR-like effects without dietary alterations. Although it is generally accepted that these compounds can promote health and lifespan, exactly how this is achieved is still being investigated. Therefore, it is necessary to understand how these compounds modulate cell function to better comprehend the aging process but also to identify other potential pro-longevity strategies. Here, we will discuss the theories of aging in relation to CR and how CR is sensed at the cellular level before discussing AAR and potential CR mimetics (CRMs) in the same contexts.

2. Caloric Restriction Attenuates Features and Processes of Cellular Aging

Aging is caused by the accumulation of numerous cellular alterations that induce cells to senescence, which consequently secrete inflammatory proteins that spread this state in neighboring cells. The accumulation of senescent cells contributes to age-associated diseases, and the clearance of these cells has been shown to delay or improve age-related phenotypes [20–22]. Key alterations associated with promoting aging (including the accumulation of senescent cells) include increased genomic instability, telomere shortening, changes in the epigenome, loss of protein homeostasis (proteostasis), deregulated nutrient sensing, mitochondrial dysfunction, stem cell exhaustion, and altered intracellular signaling [23]. CR has shown promise in attenuating age-promoting factors, reducing the number of senescent cells in a culture and model organisms [24]. CR was first reported in 1935 [5] and since then has become the most reproducible and reliable method of extending health and lifespan across model organisms, ranging from unicellular to nonhuman primates (yeast, [9], fruit flies [25], nematodes [26], crustaceans [27,28], spiders [29], lab mouse/rats [30], and monkeys [6,8,31]. At the molecular level, CR mitigates and reverses features of cellular aging. The free-radical theory of aging proposes that increased energy intake can result in more ROS as a result of oxidative phosphorylation in the mitochondria, contributing to lipid, protein, and DNA damage and advancing age (reviewed in [32,33]). CR counteracts this by lowering metabolic rates [34,35], improving DNA damage repair [36–40], and decreasing oxidative stress [41–43]. Although this theory is generally accepted, free-radical production and oxidative stress are not always decreased in response to CR [44,45]; however, increased expression of antioxidant enzymes may act as a compensatory mechanism for this.

In connection with ROS and mitochondrial dysfunction, the insulin sensitivity of cells decreases with age, increasing levels of serum glucose and insulin required for cellular responses. As a result, glucose metabolism is upregulated, increasing cell replication, decreasing the time between cell divisions, and permitting less time for the maintenance and repair of DNA [46,47]. Together, these processes push cells toward senescence. CR decreases levels of circulating glucose and insulin, increases insulin
sensitivity, and extends health and lifespan [48–51]. The upregulation of insulin-like growth factor-1 (IGF-1) also occurs with age, again promoting cell growth, division, and metabolism. CR decreases the activity of the IGF-1 signaling pathway, promoting cellular maintenance, and repair in mice [52]. However, human clinical trial data have been less consistent, with two-year CR having no impact on circulating IGF-1 levels [53,54]. Despite these findings, alternative analyses of the same trial concluded that CR decreased the rate of biological aging [55].

The hormesis model of aging proposes that low levels of stress primes cells, enabling them to prepare cellular processes required to appropriately counteract larger stress [56]. CR increases the expression of proteins involved with DNA repair, free-radical scavenging, and stress, as well as mediating ROS-producing pathways [24,40,42,43]. This model is often favored for explaining the health and lifespan benefits of CR, whereby CR activates transcription factors and mechanisms involved in regulating gene expression and protein translation to better mediate cellular stress responses [57,58] (reviewed in [59]).

2.1. How are Nutrients Sensed at the Cellular Level?

Key in promoting health and lifespan at the cellular and organismal level is the manipulation of how nutrients are detected. The target of the rapamycin (TOR) pathway is a highly conserved nutrient-sensing pathway comprising multiple proteins [60]. In mammals, the mammalian (m)TOR signaling cascade indirectly detects inputs from multiple sources, including growth signals, amino acids, and energy levels. There are two mTOR complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 is directly involved in mediating cellular responses to nutrients, although recently, mTORC2 has also been shown as nutrient-sensitive [61]. Multiple growth factor pathways (such as the insulin/IGF-1 pathway) converge upstream of mTORC1 at the tuberous sclerosis complex (TSC; a heterotrimeric complex of TSC1, TSC2, and TBC1D7 [62]). In the presence of growth factors, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway inhibits TSC by the AKT-dependent multisite phosphorylation of TSC2. This induces the dissociation of TSC from the lysosomal membrane [63], inactivating the RAS homolog enriched in brain (Rheb), which is also partially localized to the lysosome. Subsequently, mTORC1 is phosphorylated and activated by Rheb, promoting downstream cellular growth and proliferation (reviewed by [64]). Other growth factors functioning via TSC inhibition to activate mTORC1 include receptor tyrosine kinase-dependent Ras signaling, wingless-related integration site (WNT), and tumor necrosis factor α (TNFα) pathways (reviewed in [64,65]). Exactly how the TSC integrates the input of these various signals is unknown. When active, mTORC1 promotes various processes, including nucleotide, lipid, and protein synthesis, which stimulate cell growth and proliferation. In the absence of growth factors, TSC sequesters Rheb at the lysosomal membrane [66,67], inhibiting mTORC1, and shifting cellular processes toward maintenance and repair, upregulating autophagy (recycling of cellular components) and inhibiting the synthesis of new molecules.

2.2. What Downstream Effects Does Caloric Restriction Have on Genome Function?

CR does not directly inhibit mTORC1 but modulates upstream energy-sensing complexes. Adenosine monophosphate kinase (AMPK) is activated (phosphorylated by liver kinase B1; LKB1) in response to increased AMP/ATP ratios, whereas Sirtuin 1 (SIRT1) is activated by increased NAD+ levels, indicating low cellular energy availability [68–70]. AMPK and SIRT1 also activate one another, although AMPK is active much sooner (seconds/minutes) following CR when compared to SIRT1 activation (4–12 h) [71]. Perhaps SIRT1 functions later in response to CR in order to maintain AMPK activity. AMPK is also regulated by increases in intracellular Ca2+ (likely the result of hormonal changes), specifically via phosphorylation by calcium/calmodulin-dependent protein kinase kinase B (CamKKB) [72,73]. Once activated, SIRT1 deacetylates downstream targets such as p53, inhibiting p53-mediated gene expression [74,75]. However, there is potential for additional feedback as SIRT1 expression depends on interaction with Forkhead Box O3 (FOXO3a) and p53 under
CR, whereas FOXO family members are also involved in regulating IGF-1 signaling upstream of mTOR [70,76]. Moreover, SIRT1 deacetylates components of nuclear factor (NF)-κB to decrease the transcription of proinflammatory genes [77–80]. SIRT1 also deacetylates other mTOR-linked proteins, such as hypoxia-inducible factor 1α (HIF1α) [81,82], which is usually increased with age [83–85]. The deacetylation of HIF1α decreases the expression of genes involved in cell cycle progression, angiogenesis, and glucose metabolism [86].

The impact of complex signaling in response to CR and how it could potentially reverse age-linked transcriptomic changes have been examined through numerous transcriptome-wide studies across model organisms, including humans [87–95]. In general, whole-genome studies (either by microarray or RNA sequencing) have concluded that CR was able to upregulate “antiaging” genes, including genes that inhibit oxidative stress, decrease age-linked inflammation, decrease metabolism, and decrease genes involved in pathways such as IGF-1 signaling and cell cycle progression (Table 1). These findings are striking given the consensus of several publications linking pathways associated with aging to modulation by CR. Furthermore, these data highlight the importance of age at CR initiation and CR duration. For example, short-term CR induces different transcriptome profiles to long-term CR [96,97], whereas the age of CR onset also impacts its efficacy [98,99]. Analyses have been conducted over a period spanning two decades; therefore, in addition to the promising results and concordant conclusions, additional meta-analyses of datasets may provide new insights into processes governing the progression of aging as knowledge of genes and pathways evolves.

Aging is the result of numerous genetic and environmental factors that may not all be controllable in laboratory experiments. Furthermore, tissues and organs exhibit unique aging processes [100]. For example, some tissues age faster and secrete substantially more inflammatory factors. Mitochondria-rich tissues may exhibit greater susceptibility to DNA-damage-linked aging, whereas other tissues respond more to the loss of insulin and IGF-1 sensitivity. Recently, Ma and colleagues examined seven different tissues from rats for age-linked changes and their potential for reversal by CR from midlife [101]. Ma et al. also examined the composition of cell types, determining that, in accordance with changes in gene expression linked to inflammation/the immune system, cell-type composition within the rat tissues changed. Although CR rescued many age-associated changes at the genomic level, there were also CR-induced gene expression changes unique to CR in each tissue [101], corroborating other studies in mouse liver and flies [97,102]. In addition to tissue-specific changes, treatment length and dosage effects need to be considered, given that chronic or more stringent CR potentially has a different impact than shorter-term or less stringent regimes (Table 1).
Table 1. Summary of the impact of calorie restriction on aging-related pathways of calorie restriction.

| Caloric Restriction | Oxidative stress | Circulating GH/IGF-1 | Circulating Glucose/Insulin | Protein Homeostasis/Autophagy | Protein Translation | Cell Proliferation | Inflammation | Apoptosis | Neuroprotective | Energy Metabolism | Aging | DNA Repair | Immune Response | Other |
|---------------------|------------------|----------------------|----------------------------|-----------------------------|---------------------|-------------------|--------------|----------|----------------|-----------------|-------|------------|-----------------|-------|
| Yeast (2% (Non-CR) to 0.5% (CR)) [93] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↑ |
| Flies (40 days old. Control: 150 g/L sucrose, 150 g/L autolysed yeast, and 20 g/L agar, w/v or CR: 33.3% of Control: 50 g/L sucrose, 50 g/L autolysed yeast, and 20 g/L agar, w/v) [99] | ↑ | ↓ | ↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |
| Mouse (Liver, Heart, Muscle, White Adipose Tissue, Hippocampus, Cortex, Hypothalamus, Kidney, Lung, Thymus, Spinal Cord, Cochlea, Gonad, Colon (Meta-analysis)) [92] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |
| Mouse, Rats, Pigs (Meta-analysis) [91] | ↑ | ↓ | ↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |
| C57BL/6 Mouse (Male, Muscle, 76% of control, 2 months of age) [87] | ↑ | ↓ | ↓ |↑ |↑ |↑ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |
| Sprague-Dawley Rats (Male/Female; Single Cell RNAseq: Brown Adipose Tissue, White Adipose Tissue, Aorta, Kidney, Liver, Skin, Bone Marrow, Aged rats, 70% of Ad libitum from 18 to 27 months) [101] | ↑ | ↓ | ↓ |↑ |↑ |↑ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |
| C57BL/6N Mice (Male, Adipose, 85, 75 and 55% of control for 10 weeks, from 8 weeks of age) [88] | ↓ | ↑ | ↑ |↑ |↑ |↑ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |↓ |
| C57BL/6, MMTV-TGF-α Mice (Female, Thymus; Chronic Caloric Restriction: 85% of Ad libitum. From 10 weeks to 17/18 weeks) [96] | | | | | | | | | | | | | | | |Δ |
| C57BL/6, MMTV-TGF-α Mice (Female, Thymus; Intermittent Caloric Restriction, 3 weeks Ad libitum, 1 week 60% Ad libitum from 10 weeks to 17/18 weeks) [96] | | | | | | | | | | | | | | | |Δ |
Table 1. Cont.

|                      | Oxidative stress | Circulating GH/IGF-1 | Circulating Glucose/Insulin | Protein Homeostasis/Autophagy | Protein Translation | Cell Proliferation | Inflammation | Apoptosis | Anti-Cancer | Neuroprotective | Energy Metabolism | Aging | DNA Repair | Immune Response | Other |
|----------------------|------------------|----------------------|----------------------------|-------------------------------|---------------------|--------------------|---------------|-----------|-------------|----------------|-------------------|-------|------------|------------------|-------|
| B6C3F1 mice (Male, Hearts, 59% of Ad libitum from 14 months, to 30 months) [89] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Flies, (33% yeast/glucose of control) [102] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Non-human primate (Male, Skeletal Muscle; Adult onset 30% CR, 9 years) [90] | ↓ | ↓ | ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| C3B10RF1 Mice (Female, Liver; 4 weeks CR of 34 month-old mice, 2 weeks 84% Ad libitum 2 weeks 56% Ad libitum) [97] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| C3B10RF1 Mice (Female, Liver; 4 weeks CR, 56% of AL, 7 and 27 months) [97] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Human (male, female; skeletal muscle, 3–15 years nutrient adequate CR) [94] | ↑ | ↑ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Human (male, PBMC), 3 weeks 30% CR (64–85 years) [98] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Human (male, PBMC; 30% CR, 3 weeks 20–28 years) [98] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Fischer344 Rats, (Male, skeletal muscle 1.3 years, 40% CR) [11] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Human (Male/female, skeletal muscles; 58.7 ± 7.4, av. 9.6 years of -30% CR (4–20 years)) [11] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Non-human primate (Male, liver biopsy; 30% decrease in caloric intake compared to control western diet group, between 7–14 years of age) [95] | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |

AZF1P: nuclear-localized zinc-finger; HSFI1P: heat shock factor; LMX1b: LIM homeobox transcription factor 1-β; MEF3: mitochondrial editing factor 3; PRDM14: PR domain zinc finger protein 14; DMTF: Drosophila metal-responsive transcription factor; Zscan1: Zinc finger and SCAN domain-containing 1; Mt: metallothionein; Nfκbia: NFκB inhibitor α; Timp3: metalloproteinase inhibitor 3; Txnip: thioredoxin interacting protein; Zbt16: zinc finger and BTB domain-containing protein 16; Cpsf6: cleavage and polyadenylation specific factor 6; Sfpq: splicing factor proline and glutamine rich; Sfrs: serine- and arginine-rich splicing factor; YBX1: Y-Box 1; Pax6: paired box 6; Pitx2: pituitary homeobox 2; WAT: white adipose tissue.
Although understanding the aging transcriptome has progressed to the development of a transcriptomic clock (software that can predict tissue age based on transcript profiles), mechanisms behind these changes are still lacking, and pathway analyses are still vague [103]. It is important to go beyond the aging transcriptome and the impact of CR to understand how other regulatory elements of the genome are influenced. This information will further aid in the understanding of potential CR mimetics, their similarity to CR, and their ability to increase health and lifespan.

3. Amino Acid Restriction: An Alternative to Caloric Restriction?

Although CR has been studied for over a century, removing specific elements of diets is a more recently evolved area of longevity research. Amino acid restriction (AAR) centers around the theory that it is not CR per se that is responsible for increasing health and lifespan but the reduction of amino acids specifically from the diet. This consideration, combined with biochemical evidence that the presence/absence of amino acids alone is sufficient to modulate mTORC1 function [104–107], supports the proposal that AAR could be an alternative to CR.

3.1. Does Amino Acid Restriction Extend Health and Lifespan?

The restriction of all amino acids has been shown to extend lifespan in yeast [9,108], ants [109], and flies [108,110]. Additionally, the restriction of specific amino acids, such as branched-chain amino acids (BCAAs) in mice, can be as beneficial as total amino acid restriction [111], whereas in rats, the restriction of individual essential amino acids (leucine, lysine, methionine, and threonine) and total AAR reduced IGF-1 levels [112]. Tryptophan restriction increased the lifespan of rodents [113]; however, not all AAR is successful, with glutamic acid deprivation decreasing yeast lifespan [114]. Leucine restriction improves metabolic health, glucose tolerance, and insulin sensing in mice [115,116]. Protein restriction prior to surgery exhibited physiological stress protection in mice [113], whereas low-protein diets in humans under 65 years of age resulted in an overall reduction in IGF-1 levels, cancer, and mortality [117]. Furthermore, high-protein diets are linked with higher mortality rates when compared to diets based on low-carbohydrate and high vegetable content [118]. There is also an increased association with red meat and diabetes, cancer, and ischemic heart disease [119,120], whereas reduction in protein intake reduces circulating IGF-1 levels [54]. AAR-linked reductions in IGF-1 levels and improved glucose sensitivity are parallel to those observed in CR and important in extending health and lifespan. The AAR of specific amino acids further influences the post-translational modification of proteins. For example, BCAAs are important in the formation of acetic acid, a molecule used in the acetylation of histones, as well as in the regulation of autophagy, supporting findings of BCAAs in promoting lifespan-extending biological states [111,112,121]. This effect on epigenetic modification is not unique to BCAAs, with a decrease in methionine leading to decreased S-adenosyl-methionine (SAM) and reduced histone methylation [122]. Therefore, the combination of amino acids in AAR is likely important in directing which pathways are influenced within an organism and subsequent genomic and epigenomic responses. It is likely many of the beneficial impacts of total AAR, or the restriction of specific amino acids, are the result of mTORC1 inhibition and upregulated autophagy. AAR has been shown to upregulate autophagosomal–lysosomal pathways, promoting the degradation of cytoplasmic proteins and organelles, thereby providing free amino acids for protein synthesis [123,124].

Unlike CR, AAR is more complex and can be the result of restricting single or multiple amino acids. AAR strategies focusing on methionine restriction are the best defined to-date; however, this is only effective if cystine is also restricted and is therefore referred to as sulfur amino acid restriction (SAAR). In addition to increasing lifespan [114,125–127], SAAR lowers levels of serum IGF-1, insulin, glucose, and thyroid hormone, increasing insulin sensitivity, decreasing body weight, improving resistance to oxidative stress in various mice and rat strains [128–133], and decreasing mitochondrial ROS production and protein oxidation [134,135]. Additionally, in mice, SAAR prevents the onset of T2D [136] and
extends the lifespan of progeroid-models [137,138]. Therefore, as with CR, SAAR counteracts many of the molecular processes associated with aging.

Although AAR is capable of extending health and lifespan, the deprivation of different amino acids differentially impacts the transcriptome. When compared to 15 other amino acids in breast and prostate cancer cells, the restriction of methionine was able to elicit the largest transcriptional changes, likely due in part to additional impacts on the epigenome [122]. As cancer cells are often hyperproliferative and have dysregulated cell cycles, to better understand the impact of AAR in aging, the replication of these studies in noncancerous human cell lines would be beneficial. Evidence for amino-acid-specific effects is provided by methionine restriction, which extends the lifespan of *Drosophila melanogaster*, albeit not to the same degree as total AAR [108]. Similarly, leucine restriction exerts similar benefits as methionine restriction (although not as consistently) [116]. In flies, the restriction of tryptophan or arginine required the general control nonderepressible 2 (GCN2) protein (a protein kinase that specifically responds to amino acid levels) to achieve health-promoting effects, whereas others (histidine and arginine) did not [139]. Finally, protein-restricted mice supplemented with different BCAAs exhibited varied metabolic profiles [111,140]. This may be due to the different sensitivity of mTORC1 to each amino acid, in particular leucine and arginine [104]. Although there is much evidence regarding the benefits of either total AAR or SAAR restriction, it will be important to determine how healthy tissues and organisms respond to the removal of individual amino acids. Furthermore, understanding genomic changes and mechanisms mediating these processes will aid in the development of diets in which amino acid levels can be manipulated to treat many age-linked diseases without reducing overall caloric intake.

3.2. Is Amino Acid Sensing also Regulated through mTOR?

Although some organisms can synthesize all amino acids, mammals must rely on extracellular sources for a subset of amino acids (termed essential amino acids). Amino acid levels can also be used to modulate mTOR activity to direct subsequent cellular processes [104–107]. Amino acid sensing by mTOR is complex, with potentially distinct upstream receptors for each amino acid. Few of these have been identified; however, in general, amino acid depletion downregulates mTORC1, resulting in decreased protein synthesis and cell proliferation. This inactivation also promotes autophagy, catabolizing pre-existing molecules for the amino acids required to prevent starvation [141]. If enough autophagy occurs, mTORC1 is upregulated.

mTORC1 is localized to the lysosomal surface in the presence of amino acids. In general, amino acid sensors indirectly promote stable dimerization between RagA/B and RagC/D, which are targeted to the lysosome via Ragulator (as the RagA/B/C/D GTPases do not have a lipid-targeting signal, this acts as an intermediate). To interact with mTORC1 (via the raptor subunit), RagA/B must be GTP loaded and RagC/D must be GDP loaded. Rheb then activates mTOR (mTORC1) in a Rag-dependent manner [142–144]. If artificially anchored to the lysosome, mTORC1 becomes insensitive to amino acids while still responding to insulin levels [142]. Therefore, it is likely that Rheb and Rag form part of a regulatory network that enables appropriate mTORC1 activation in response to a balance of amino acids and growth factors.

Upstream of the Rag GTPases are cellular amino acid sensors. Of these, the sensors for arginine and leucine (sestrin2 and cytosolic arginine sensor for mTORC1 (CASTOR)) [145–148] bind their respective amino acids, disrupting interactions with and activating GTPase-activating protein toward Rags (GATOR2), inhibiting GATOR1, and activating RagA/B and, ultimately, mTORC1 [145,149,150] (Figure 1C). In the absence of arginine/leucine, their respective sensors are bound to GATOR2, inhibiting it as well as mTORC1 (Figure 1D). Unlike arginine/leucine, methionine is sensed by the S-adenosyl-methionine (SAM) sensor (SAMTOR) via the presence of its metabolite SAM. SAM binds SAMTOR, dissociating it from GATOR1. Amino acids are also sensed from the lysosome; for example, SLC39A9 is a lysosomal arginine sensor that interacts with the Rag-GTPase-Ragulator-v-ATPase
complex to activate mTORC1 (reviewed by [60]). This process may couple the release of essential amino acids from the lysosome to activation of mTORC1 and cell growth.

**Figure 1.** How are nutrients sensed at the cellular level? The mTOR and GCN2 pathways. (A) mTOR signaling in response to plentiful nutrient (growth hormone, insulin) supply. Under conditions of plentiful nutrients, growth factors and insulin inhibit TSC1/2, leading to the inhibition of Rheb and the induction of mTORC1 at the lysosomal surface. mTORC1 upregulation results in autophagy inhibition and the promotion of protein translation, cell growth, and proliferation. Under these conditions, cellular ATP levels increase, reflective of plentiful nutrient status. ATP increase inhibits AMPK, modulating the AMPK-SIRT1-LKB1 feedback loop and inducing mTORC1. Independently of mTORC1, SIRT1 also downregulates the expression of FOXO3a and promotes the synthesis of genes/proteins involved in the cell cycle, as well as response inflammation and cellular stress (when required). (B) mTOR signaling under conditions of caloric restriction. In the absence of nutrients (or under conditions of caloric restriction; CR) TSC1/2 are activated, Rheb is GDP loaded, and mTORC1 is inhibited by undocking from the lysosomal surface. This promotes autophagy and inhibits protein translation, cell growth, and proliferation. Simultaneously, ATP levels decrease, increasing the AMP/ATP ratio indicative of low cellular energy status, activating AMPK, and modulating the AMPK-SIRT1-LKB1 feedback loop. In addition, proinflammatory transcription/translation is inhibited, metabolism is decreased, and longevity promoting FOXO3a is translocated to the nucleus to regulate its target genes. (C) mTOR signaling under plentiful amino acid availability. In the presence of amino acids, mTORC1 integrates signals from multiple amino acid receptors: (inhibited sestrin (leucine), castor (arginine), or samtor (methionine) complex formation), glutamine sensor ARF-1, lysosomal arginine sensor SLC38A9, and lysosomal amino acid sensor v-ATPase. In the presence of all amino acids, mTORC1 is active and promotes cellular growth and proliferation. If individual amino acids are absent, this could result in mTORC1 inhibition and shift cells to a status of amino acid restriction (AAR). (D) mTOR and GCN2 under conditions of amino acid restriction (AAR). In the absence of amino acids, mTORC1 is inhibited, promoting the previously mentioned prolongevity factors, including autophagy and preventing cell proliferation. GCN2 is activated under conditions of AAR by the binding of uncharged tRNAs. eIF2α is then converted to eIF2β, which cycles between GTP- and GDP-loaded states, regulated by GADD34. eIF2B promotes translocation of ATF4 to the nucleus, where it regulates subsequent expression of genes with amino acid response elements (AARE). NRF2 is also upregulated in response to AAR and can promote upregulation of ATF4. ATF2 similarly binds cAMP/AP-1 motifs to promote the expression of GADD34. Created with BioRender.com.
Beyond utilizing specific amino acid receptors, mTORC1 also responds to amino acid signaling via Rag-GTPase-independent methods. Glutamine requires lysosomal H^+ ATPase (v-ATPase) and vesicle trafficking ADP ribosylation factor (Arf-1 GTPase) [151,152]. Glutamine has also been reported to activate mTORC1 through a Rag-dependent mechanism [153]. The ability of AAR to modulate mTOR signaling to inhibit mTORC1 and, subsequently, upregulate similar downstream processes as seen with CR, makes it a strong candidate as an alternative to CR.

4. Are Amino Acid Restriction and Caloric Restriction the Same?

In addition to modulating mTORC1 function, AAR also mediates mTORC1-independent functions via the integrated stress response (ISR). The ISR rapidly assimilates extracellular stress signals, such as AAR, through protein kinases that function to prevent the exhaustion of cellular resources. This process also likely occurs in response to CR, thereby reducing numerous energy status indicators, including levels of amino acids and growth factors. As intracellular amino acid levels decrease, so do levels of charged tRNA. Uncharged tRNA then bind and activate GCN2, which then phosphorylates eukaryotic initiation factor 2 (eIF2)α, which is converted into an inhibitor of eIF2β. The inhibition of eIF2β will slow the rate at which eIF2α is reloaded with GTP, ultimately reducing GTP-GDP exchange rates on eIF2α, necessary for mRNA translation re-initiation and decreasing global translation. Although global translation is decreased, the translation of specific transcription factors such as activating transcription factor (ATF) 2, ATF4, ATF5, and growth arrest and DNA-damage-inducible protein (GADD34) are increased [154] (reviewed by [155]). ATF4 translocates to the nucleus where it binds amino acid response elements (AAREs), upregulating the expression of amino acid transporters, metabolic regulators, antioxidant defenses, and other homeostatic processes to promote the re-establishment of homeostatic cellular conditions. GADD34 enables feedback signaling to permit the translation of upregulated stress-response genes [156]. Some ATF4-regulated genes require the phosphorylation of ATF2 to upregulate transcription. ATF2 specifically targets genes that do not respond to other amino acid response linked transcription factors [157]. Therefore, AAR can be regulated independently of the mTOR pathway. In addition, GCN2 is required to extend lifespan in yeast and flies in response to AAR [114,158], with GCN2-deficient organisms displaying aging phenotypes. As downstream processes regulated by GCN2 and mTORC1 significantly reduce protein translation, this is one potential mechanism by which longevity is promoted. GCN2 signaling is responsive to CR likely through a decrease in amino acids and therefore plays an important role in mediating the response to CR, albeit more specific to amino acid sensing. The role of mTORC1 in response to AAR and CR has been extensively examined; however, the role of GCN2 in promoting health and lifespan remains relatively unexplored.

The IRS and mTOR pathways feedback on one another, linking cellular responses to CR and AAR in promoting health and lifespan. One important molecule involved in this feedback is fibroblast growth factor 21 (FGF21), which is upregulated by ATF2/4. The FGF21 promoter contains an AARE [159,160], and FGF21 is implicated in promoting the beneficial effects of CR and AAR/SAAR [161,162]. Additionally, the overexpression of FGF21 increases lifespan [163] and prevents cellular senescence via SIRT1 [164], demonstrating its significant role in longevity and well-established longevity-promoting pathways. Counterintuitively to its upregulation in response to CR and AAR, FGF21 levels are also increased with age [165–167]. It has been proposed that this could be due to insensitivity to FGF21 levels/loss of FGF21 receptors [166,168,169]; however, findings are mixed [167,170]. Although the reason for an increase in FGF21 levels in aging, as well as in response to CR, is unclear, there is a consensus that this molecule upregulates metabolism and reduces the impacts of chronic disease (reviewed by [171]) by preventing insulin resistance ([172,173]). FGF21 also activates the mTORC1-S6K axis via mitogen activator protein kinase (MAPK), perhaps as the result of feedback signaling from increased amino acid availability due to autophagy, with increased mTORC1 levels demonstrated to mediate the beneficial impacts of FGF21 in vitro [174]. As a molecule primarily
secreted from the liver, FGF21 could act as a signal of global energy status across many tissues, promoting energy-saving states in other cells.

5. Caloric Restriction Mimetics

CR clearly has positive impacts on health and lifespan. However, with 39% of the world’s population already overweight (World Health Organization, 2020), this is a difficult strategy to implement. Alternatively, a variety of compounds exist that mimic CR without having to restrict food intake. Caloric restriction mimetics (CRMs) often function via similar pathways to CR, such as the mTOR signaling cascade, and have the potential to be used as treatments to prevent the development of age-related pathologies and promote healthy aging.

5.1. Rapamycin

Rapamycin, also known as sirolimus, was initially isolated in 1964 from soil containing Streptomyces hygroscopicus on Rapa Nui (Easter Island) during a Canadian expedition to the South Pacific. First described as an antifungal, the immunosuppressive and antitumor properties of rapamycin led to its frequent use in clinical settings [175]. In 2006, it was proposed that rapamycin could be used to slow aging and improve many physiological functions that deteriorate with age in humans, making this compound one of the first CRMs [176]. Rapamycin forms a complex with the FK506-binding protein 12 (FKBP12), which induces inhibition of mTORC1 and subsequently the mTOR pathway (Figure 2A) [177,178]. Similar to CR, the rapamycin-mediated inhibition of mTORC1 decreases cellular growth, proliferation, and protein translation [179–181] and upregulates autophagy [182,183], thus promoting health and lifespan.

In addition to its lifespan-extending properties, additional studies have shown that rapamycin can ameliorate age-related disease phenotypes in cell-based models of cancer [184–186], CVD [187,188], premature aging diseases (e.g., HGPS [189–191]), and ND [192]. These findings can be recapitulated at the organismal level, including in ND (e.g., amyotrophic lateral sclerosis [193], tauopathies [194], Alzheimer’s disease [195–197], Parkinson’s disease [198]), cancer [199,200], obesity [201], disrupted circadian clock [202,203], and laminopathies [204,205]. Furthermore, rapamycin pretreatment improves the success of pancreatic islet cell engraftment through the inhibition of inflammatory chemokines in mice models and human patients with type I diabetes [206]. The results of these studies have encouraged the exploration of rapamycin in humans beyond its use as an immunosuppressant following organ transplantation [207–209]. For example, when applied topically, rapamycin can improve the clinical appearance of the skin [210], but, more importantly, it can prevent insulin resistance [211]. Therefore, like CR, rapamycin has numerous benefits in various disease states to promote healthier aging across species.

There is evidence indicating that rapamycin in a bona fide CRM due to its induction of autophagy. This is supported by combinatorial studies of CR and rapamycin, in which the same pathway is targeted [212]. However, there is also evidence that, unlike CR, which improves insulin sensitivity and glucose tolerance, rapamycin promotes insulin resistance [213]. This could be the result of chronic rapamycin treatment, which induces starvation pseudodiabetes (SPD), also triggered in response to prolonged fasting [214,215]. It is possible that in models where rapamycin induces SPD, the dose is too high and mimics starvation rather than CR. To further support that rapamycin functions alternatively to CR, Unnikrishnan et al. [14] demonstrated that CR, in combination with rapamycin, improved glucose and insulin intolerance when compared to control or rapamycin alone, indicating that CR could alleviate the secondary effect of rapamycin on glucose metabolism Although this may be a cause for concern in considering rapamycin as a lifespan-promoting compound, or even a CRM, there are numerous experimental considerations. For example, the increase in insulin insensitivity is not observed in all mouse strains and treatment conditions are often not consistent across studies (e.g., dose and length). Nevertheless, rapamycin-fed model organisms frequently live longer, healthier lives.
Figure 2. (A) Downstream effects of mTOR signaling in response to rapamycin and rapalogs. The inhibition of mTORC1 results in the decrease of the inflammatory response and promotion of apoptosis through regulation of IκB kinase. ULK1 is also inhibited, promoting autophagy. Furthermore, the activity of the eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and S6K1 proteins is decreased, which results in diminished cell growth, proliferation, and protein translation. The inhibition of mTORC1 also decreases p53-mediated gene expression. Moreover, through the inhibition of S6K1, Akt activity is upregulated, generating a feedback loop to the products of decreased mTORC1 activity, specifically via the inhibition of TSC1/2 and GSK-3β. IRS-1: insulin receptor substrate 1; CCL-2: C-C motif chemokine ligand 2, BCL-2: B-cell lymphoma 2; BCL-XL: B-cell lymphoma-extra-large. (B) Downstream effects of mTOR, AMPK, and SIRT1 signaling in response to metformin and resveratrol. Metformin exposure decreases mitochondrial function, increasing the AMP/ATP ratio and NAD\(^+\) levels. The increased AMP/ATP ratio activates AMPK, which, in turn, decreases protein translation, cell growth/proliferation, and stimulates autophagy and apoptosis. AMP also activates the nuclear factor erythroid 2-related factor 2 (NRF2), which triggers the synthesis of genes involved in the antioxidant response (ARE). Through inhibition by phosphorylation of the mitogen-activated protein kinase (MAPK1) and CCAAT-enhancer-binding homologous protein, AMPK inhibits and activates the c-Jun N-terminal kinase (which is involved in inflammation, JNK). Furthermore, AMPK also reduces the inflammatory response through the inhibition of the signal transducer and activator of transcription (STAT3). In the presence of resveratrol, the most potent inducer of SIRT1, inflammatory proteins are decreased by the inhibition of NF-κB. Finally, AMPK is also activated by phosphorylation of the liver kinase B1 (LKB1) and deacetylation of SIRT1, creating a feedback loop.

To establish whether rapamycin is a CRM, it is important to consider changes in specific genes that are markers of CRM function. Cyclin D1, a cell cycle marker, increased in response to both CR and rapamycin in mouse liver tissue. However, transcript levels of other proteins involved in the same cellular process, such as p16, p21, and p53, were decreased [212,216] (Table 2). Unnikrishnan and colleagues also identified transcriptomic changes in the genome of mouse livers under regimes of ad libitum, CR, and rapamycin treatment [14]. Rapamycin was found to have overlapping, but distinct, gene expression profiles to those of ad libitum or CR [217], supporting that rapamycin is not a CRM. This could also provide evidence that to achieve health and lifespan extension, a subset of transcriptomic changes in response to CR/AAR/CRM is required, and other changes may be condition- or compound-specific and not essential for the desired effects. Furthermore, when combined, rapamycin and CR have greater impacts on both the transcriptome and metabolome.
of mice than when applied separately [217], with <20% of mRNA transcripts shared by CR and rapamycin. Moreover, of genes changing by CR, 74% matched genes previously identified in response to CR (using the GenDR database), but only 7.5% of rapamycin-induced gene expression changes were found in the same database. In comparing rapamycin and CR in white adipose tissue (WAT) of mice, fewer transcripts changed in response to rapamycin [216]. Similarly, CR induced greater changes in the yeast transcriptome than rapamycin, with CR upregulating genes for autophagy and \( \beta \)-oxidation, whereas rapamycin increased the expression of enzymes involved in the degradation of energy-storage molecules [218]. Both rapamycin and CR had beneficial impacts on reproduction in mice (increased preservation of ovarian primordial follicular reserves); however, the two treatments again exhibited divergent metabolic effects. Regardless, both were associated with higher transcript levels encoding the pro-longevity factor FOXO3a [219]. Therefore, although CR and rapamycin both function to extend health and lifespan consistently across organisms, the impacts of these compounds are transcriptomically varied.
Table 2. Summary of the effects of rapamycin and rapalogs on aging-related pathways.

| Rapamycin                                                                 | Protein Homeostasis/Autophagy | Hormesis/Stress Priming | Protein Translation | Cell Proliferation | Inflammation | Apoptosis | Anti-Cancer | Neuroprotective | Other |
|--------------------------------------------------------------------------|------------------------------|-------------------------|---------------------|--------------------|--------------|-----------|-------------|-----------------|-------|
| Mouse Oocyte (100 nm, 2 h) [181]                                          |                              |                         |                     |                    |              |           |             |                 |       |
| Juvenile Human Fibroblasts (2DD; 500 nm, 120 h) [220]                     | ↑                            | ↓                       | ↓                   |                    |              |           |             |                 |       |
| Maternally Inherited Leigh Syndrome Human iPS (20 nm, 6 h) [192]         | ↑                            | ↓                       | ↓                   |                    |              |           |             |                 |       |
| Amyotrophic Lateral Sclerosis Mice Spinal Cord (2.33 mg/kg/day, 60 days) [193] | ↑                            | ↓                       | ↓                   |                    |              |           |             |                 |       |
| Human Prostate Cancer Cell Lines (LNCaP, 22RV1, PC3, DU145; 20 nm, 72 h) [185] | ↓                            | ↓                       | ↑                   |                    |              |           |             |                 |       |
| C57BL/6 mice (endotoxin-uveitis and retinitis induced: retinal inflammation model; 6.0 mg/kg/day) [187] | ↓                            |                         |                     |                    |              |           |             |                 |       |
| Wistar Rats (Heart Failure (HF) Model; 1.4 mg/kg/day, from 8 weeks old) [187] | ↑                            | ↓                       | ↓                   |                    |              |           |             |                 |       |
| Sprague-Dawley Rats (Cerebral Ischemia (CI); Kidney and Blood Tissues, Males; 1 mg/kg, 0.5 h prior to CI) [183] | ↑                            | ↓                       | ↓                   |                    |              |           |             |                 |       |
| 7PA2 cells (APP familial mutation; 0.5 mg/mL, 24 h) [197]                | ↑                            | ↓                       | ↓                   |                    |              |           |             |                 |       |
| 3xTg-AD mice (AD model; 2.24 mg/kg, 10 weeks) [197]                      | ↑                            | ↓                       | ↑                   |                    |              |           |             |                 |       |
| ND-model (20 nm, 6 h) [192]                                              | ↑                            | ↓                       | ↓                   |                    | ↑            |           |             |                 |       |
| SAMP8 mice neurons (ND model; 0.5 µM, 72 h) [194]                        | ↑                            | ↓                       | ↓                   |                    | ↓            |           |             |                 |       |
| Humans (0.001% topically. 4 months) [210]                               | ↓                            |                         |                     |                    |              |           |             |                 |       |
| Lmna-/- BAT, WAT (8 mg/kg, every other day) [204]                         |                              |                         |                     |                    |              |           |             |                 |       |

- Up-regulation of Cytokine-cytokine receptor signalling, regulated by STAT5A/B TF
- Alleviates mitochondrial defects
- Suppressed immune response/increased mouse survival
- Correlation between Cyclin D1 and rapamycin sensitivity of prostate cancer cells
- Decreased NF-κB activity, neuroprotection (decreased rhodopsin)
- Clearance of ND-linked protein aggregates
- Clearance of ND-linked protein aggregates, ↑ autophagy (↑ BCL-2, ATG13; ↓ULK1); ↓ inflammation (↓TNF-a, IL-1b)
- Promote energy balance
- Clearance of ND-linked protein aggregates,
- ↓ cellular senescence (↓ p16, p21, p53); Decrease in fine wrinkling (↑ collagen VII)
- ↓ lipolysis, energy expenditure, fatty acid oxidation; ↑ thermogenesis
Table 2. Cont.

| Protein Homeostasis/Autophagy | Hormesis/Stress Priming | Protein Translation | Cell Proliferation | Inflammation | Apoptosis | Anti-Cancer | Neuroprotective | Other |
|-------------------------------|-------------------------|--------------------|-------------------|-------------|----------|------------|----------------|-------|
| **Everolimus**                |                         |                    |                   |             |          |            |                 |       |
| Human T1D (1 month before islet transplant; 0.1 mg/kgbw/day) [206] |                         |                    |                   | ↓           | ↓        |            |                 |       |
| Human melanoma cells: Lu1205, WM793 (5 nm, 24 h) [221] |                         |                    | ↓                 |             |          | ↓          |                 |       |
| 3xTg-AD mice (AD model) (One dose of 0.167 µg/µL in a volume of 6 µL) [222] |                         |                    |                   |             |          | ↓          |                 |       |
| Elderly Humans (0.5–20 mg/week, 6 weeks) [223] |                         |                    | ↓                 |             |          |            | Enhanced immune response |       |
| RT112 and T24 cells (bladder cancer cell models; 0.5–500 nM, 1 h) [224] |                         |                    | ↓                 | ↑          | ↑        | ↑          | AKT phosphorylation (feedback signalling; GSK3-β phosphorylation) |       |
| Post-menopausal women with early breast cancer (5 mg/day, 14 days) [225] |                         |                    | ↓                 | ↓          | ↓        | ↓          | Ki67, S6K1, AKT phosphorylation |       |
| HEK293 cells (liver cancer cell model) (1–20 nm, 24 h) [226] |                         |                    | ↓                 |             |          | ↓          | c-Myc |       |
| HGPS Fibroblasts (0.1 µM, 2 weeks) [227] |                         | ↑                   |                   |             |          |            | Reversed some cellular aging phenotypes |       |

STAT5A/B: signal transducer and activator of transcription 5; BCL-2: B-cell lymphoma 2; ATG: autophagy-related genes; CCL: C-C motif chemokine ligand; S6K1: ribosomal protein S6 kinase β-1; BAT: brown adipose tissue.
5.2. Rapalogs: Rapamycin Analogs

Rapamycin has many benefits; however, its poor solubility, bioavailability, and pharmacokinetics, as well as side- and off-target effects [228], have led to the development of rapalogs. Rapalogs are synthetic analogs of rapamycin that aim to improve clinical outcomes of rapamycin, with fewer off-target effects. These rapalogs, including everolimus, temsirolimus, and ridaforolimus, have been examined to determine if they can also extend health and lifespan.

Everolimus (RAD001) is an orally administered rapalog that has been reported to have the same therapeutic properties as rapamycin with higher thermal stability, greater solubility, and improved pharmacokinetics [229]. Everolimus binds to FKBP12, inhibiting mTORC1, and results in the downregulation of the PI3K/AKT/mTOR pathway (Figure 2A). In some human cancers, this exerts an antiproliferative effect, inhibiting migration and angiogenesis [230], parallel to CR, AAR, and rapamycin [230]. Everolimus alone, or combined with other anticancer agents, has been shown to attenuate cancer cell growth, promote increased cell death, and increase patient survival [221,224,225,231,232]. Sabine et al. [233] observed that patients with early-stage breast cancer had decreased expression of genes involved in cell cycle and proliferation, pyrimidine metabolism, and p53 signaling pathways in response to everolimus. However, the genes involved in the mTOR pathway were not differentially expressed after everolimus treatment, indicating that this compound can modulate other pathways in addition to mTOR [233]. Genes involved in the PI3K/AKT/mTOR pathway are highly responsive to everolimus [234], and as such, everolimus is routinely used in cancer treatments in Europe and the United States. The widespread use of everolimus in clinics highlights the benefits of this compound over rapamycin.

As a derivative of rapamycin, everolimus has also been proposed as a pro-longevity compound and CRM. Everolimus prolongs the survival of HGPS cell models and rescues age-linked cellular defects [227]. In mice, everolimus attenuates neurological decline and vascular dementia [235] as well as decreasing neuronal loss and oxidative stress [236]. Additionally, everolimus reduced amyloid precursor protein (APP) levels, the amyloidogenic Aβ peptide, as well as levels of phosphorylated tau, which are hallmarks of AD pathology [222]. In aged rats, everolimus reversed 37% of age-linked transcriptional changes in kidney tissue, including the reversal of the upregulation of inflammatory response, interferon alpha/gamma response, and apoptosis [226] and, in mice, downregulated glucose metabolism [237] (Table 2). Everolimus also reduces cytokine production [231,238] in liver transplant patients, improves immune function, and prevents immune-induced senescence in elderly humans [223]. In addition to these longevity-promoting effects, everolimus downregulated the protein c-Myc [226]. Increased c-Myc levels are associated with aging [239] and have been reported to respond to rapamycin treatments [240,241] but rarely to CR [242]. c-Myc and SIRT1 function in a negative feedback loop; c-Myc binds the SIRT1 promoter to increase expression, with SIRT1 deacetylating c-Myc to decrease its DNA binding activity [243]. This feedback loop functions independently of mTOR to regulate downstream targets associated with health and lifespan [241]. Furthermore, c-Myc can upregulate ATF4 via GCN2, linking this protein to AAR responses [244]. These complex mechanistic relationships are still under investigation; however, they support the divergence between rapamycin/rapalogs and CR while also highlighting the importance of pathways other than mTOR in regulating the response to longevity-promoting interventions (LPIs).

Both temsirolimus and ridaforolimus have improved solubility and pharmacokinetics over rapamycin [245,246]. Both compounds have been shown to inhibit the growth of cancer cells, with ridaforolimus currently being tested in phase I and II clinical trials. In addition to its potential application as a cancer therapy, temsirolimus ameliorates age-linked phenotypes in a HGPS cell model [247], attenuates tauopathies [248], and clears AD-related Aβ by inducing autophagy in preclinical models [249]. Although promising, information on molecular mechanisms or transcriptomics of these rapalogs is limited.

Rapalogs are associated with numerous beneficial effects linked with healthier aging, such as decreasing inflammation and circulating IGF-1 levels; however, like rapamycin, these derivatives
also induce glucose insensitivity. Regardless, these compounds have been documented to reverse age-associated phenotypes in HGPS cell models and ND; benefits that may outweigh potential negative impacts. Notably, most of the research done for these derivatives has been conducted in cancer-based models; therefore, the impact they could have on normal cells/organisms is unclear. Furthermore, the impact of these compounds on genome function is poorly defined, making it difficult to establish whether rapalogs are CRMs; however, although these compounds overlap in their function via inhibition of mTOR, they also likely influence pathways distinct to those altered by CR.

5.3. Resveratrol

Resveratrol (3,5,4′-trihydroxystilbene) is a polyphenol produced by plants in response to physiological damage and is found in foods such as grapes, berries, pine nuts, and legumes [250]. Mediterranean diets are rich in resveratrol (as well as many other polyphenols) and have been associated with promoting positive markers of health. For example, the consumption of resveratrol via red wine has been linked to the lower incidence of CVD in France [251] despite high-fat diets. This proposed effect on CVD is due to resveratrol’s antioxidant and anti-inflammatory effects, which have been recapitulated in nonhuman primates [252,253] and have further been associated with the alleviation of age-related diseases [254]. As with other CRMs, resveratrol inhibits cancer cell growth (leukemia [255], breast [256], liver [257], and gastric [258]) and has anticancer effects in multiple animal models ([259–265]) as well as the capacity to suppress metastasis (reviewed in [266]). Additionally, resveratrol has been documented to decrease age-dependent cognitive decline and AD-like pathologies [267]. In human trials, resveratrol has been shown to regulate neuroinflammation in AD patients [267], improve cognitive function in adults with T2D [268], improve insulin sensitivity [269], and suppress postprandial glucagon [270,271] in overweight individuals. Moreover, in healthy humans, resveratrol improves cerebral blood flow and cognitive performance [272] and decreases IGF-1 levels [273] (Table 3). Since the mentioned pathologies (including cancer and T2D) are often associated with age, resveratrol has been proposed as a CRM and antiaging drug, with evidence demonstrating lifespan increases [274–279].

Resveratrol generally functions via interaction with, and the activation of, SIRT1, although at higher doses, it also interacts with, and activates, AMPK [280] (Figure 2B). As noted previously, SIRT1 and AMPK feedback to one another in response to CR and proposed CRMs. SIRT1 deacetylates proteins, such as p53, FOXO3a, NF-κB, and peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) through a NAD⁺ substrate that is converted to NAM (reviewed by [281]). Given the role of NAD⁺ as a potent activator of SIRT1, this molecule is key in regulating the energy metabolism and cellular stress mediation effects of resveratrol [279]. To compare the impact of CR to resveratrol, Li and colleagues found that both treatments can upregulate SIRT1, increasing the expression of the pro-longevity protein FOXO3a and the activity of telomerase leading to inhibition of senescence and apoptosis; notably, the impact of resveratrol was greater than that of CR [16]. Additionally, resveratrol reduced the expression of genes encoding inflammatory markers, including IL-6, chemokine (C-C motif) ligand 3 (CCL3), IL-1β, and TNF-α [282] in humans. Analysis of microarray data from breast cancer cells found that 48 h of resveratrol treatment downregulated key genes related to the cell cycle, DNA metabolic process, cellular response to stress, and regulation of cell death [283]. The downregulation of these pathways is similar to that observed in response to CR, maintaining insulin sensitivity [17] and decreasing circulating IGF-1 levels [284]. However, resveratrol was not able to recapitulate the effects of CR in mice [285] and induced differing metabolomes [286]. Limited whole-transcriptome impacts of resveratrol have been generated. In aged mice, resveratrol had minimal effects (note: the mice in question were fasting during treatment, which may impact the interpretation of the data). However, changes in neuron synaptosome function [287] show the potential of resveratrol in treating ND diseases. Resveratrol promotes antioxidant enzyme function, maintains mitochondrial function, and reduces inflammation more than other potential CRMs. Therefore, it is also unlikely an exact mimetic of CR. More information on the impact of resveratrol on the genome, and potential transcription factors
regulating these genome-wide changes could provide interesting mechanistic insights into resveratrol’s antiaging properties.

As with other CRMs, resveratrol can exhibit harmful side effects linked to dosage concentration and duration. For example, in indomethacin-induced gastric ulcerated mice, low-dose resveratrol was protective, whereas higher doses delayed healing [288]. Additionally, resveratrol concentrations that induce cancer cell death are also cytotoxic to healthy cells and tissues (reviewed in [289]). Resveratrol metabolites, produced under certain conditions (e.g., o-Quinone), also exhibit detrimental effects, inducing oxidative stress and alkylation [290,291]. It has been suggested that these harmful effects are the result of resveratrol modulating oxidative stress, functioning as an antioxidant or pro-oxidant compound dependent on dosage concentration, duration, and environment. Specifically, high concentrations of resveratrol inhibit DNA repair pathways, triggering ROS production, and inducing cell death (the opposite of which is true for low-dose treatments in promoting health and lifespan) (reviewed in [289]). Further research into the conditions that regulate resveratrol function as a pro- or antioxidant is required to better understand its potential in extending health and lifespan.
Table 3. Summary of the effects of metformin and resveratrol on aging-related pathways.

| Resveratrol                                                                 | Oxidative Stress | Protein Homeostasis/Autophagy | Protein Translation | Cell Proliferation | Inflammation | Apoptosis | Anti-Cancer | Neuroprotective | Other                  |
|----------------------------------------------------------------------------|------------------|-----------------------------|--------------------|-------------------|--------------|-----------|-------------|-----------------|-----------------------|
| Yeast (2–5 µm) [279]                                                       |                  |                             |                    |                   | ↑            |           |             |                 | ↑ yeast survival, ↑ SIRT1 activity |
| Kasumi-1 Xenograft Mice (Leukemia Cell Model; 5–20 mg/kg/day, 24 days) [255] |                  |                             |                    |                   | ↑            | ↑         |             |                 |                       |
| Kasumi-1 (Leukemia Cell Model; 50 µm, 6 h) [258]                           |                  |                             |                    |                   | ↑            | ↑         |             |                 |                       |
| MCF-10A-Tr xenograft mice (breast cancer animal model (40 mg/kg/day, 30 days) [261] | ↓                | ↓                          | ↑                  | ↑                 | ↑            | ↑         |             |                 |                       |
| AD Patients (500–2000 mg/day, 52 weeks) [267]                              | ↓                |                            |                    |                   |              |           |             |                 |                       |
| AβPP/PS1 mice (AD animal model; 16 mg/kg/day, 10 months) [292]             |                  |                             |                    |                   |              |           |             |                 |                       |
| TCDD CYP1A induced expression induced in MCF-10A cells (breast cancer cell model; 5–50 µM, 3 days) [293] | ↓                |                            |                    |                   |              |           |             |                 |                       |
| Metformin                                                                  |                  |                             |                    |                   | ↑            | ↑         | ↑           |                 |                       |
| HepG2 cells (liver cancer model; 1–10 mM, 24 h) [294]                      | ↓                | ↑                          | ↑                  |                   | ↑ caspase 3, ↑ AKT phosphorylation |
| HepG2 xenograft mice fed with 60% high-fat diet (250 mg/kg bw/day, 4 weeks) [294] | ↓                |                             |                    |                   | ↑ Cyclin D1, ↑ hypoxia induction and maintenance of micro vessel density; ↑ CA-9, ↓ VEGFR |
| Bone marrow mice-derived macrophages (BMDMs; 2 mM, 24 h) [295]            | ↓                |                             |                    |                   | ↑ IL-6, ↓ TNF-α |
| High fat-fed C57Bl6 male mice (300 mg/kg bw/day-11 weeks) [295]            | ↓                |                             |                    |                   | ↑            | ↑         |             |                 |                       |

MMP9: matrix metalloproteinase 9; BACE: beta-secretase 1; ADAM10: a disintegrin and metalloproteinase domain-containing protein 10; CYP1: cytochrome P450; CA-9: carbonic anhydrase 9; VEGFR: Vascular endothelial growth factor receptor; CK19: cytokeratin-19; α-SMA: alpha smooth muscle actin; GLUT1: glucose transporter 1; GREB1: growth-regulating estrogen receptor binding 1; AP-1: activator protein 1; ARE: antioxidant response elements; SOD: superoxide dismutase; CAT: catalase; GHS: glycinyl-histidinyl-serine; BDNF: brain-derived neurotrophic factor; ER: endoplasmic reticulum.
5.4. Metformin

Metformin (N,N-dimethylimidodicarbonimidic diamide), derived from the French Lilac (G. officinalis), is a commonly used treatment for T2D [296]. Metformin increases AMP/ATP ratios, indicating low cellular energy status and activating AMPK and sirtuin proteins [297]. Surprisingly, despite its widespread use, the exact mechanism by which metformin alters AMP/ATP ratios remains unclear. Metformin likely influences AMPK levels by modulating mitochondrial function and ATP production, triggering AMPK activation and indirectly inhibiting mTORC1 [298], which may parallel CR (Figure 2B). Consequently, the potential of metformin as a CRM relies on its mediation of mitochondrial metabolism and insulin signaling [299,300]. As with CR/AAR and other CRMs, metformin has shown antitumoral effects in various cancers [294,301–304], neuroprotective effects in ND diseases [305,306], and benefit in treating epilepsy [307]. Metformin also shows potential as an adjuvant cancer therapy [308,309] and is associated with decreased cancer incidence in the general population [310]. Furthermore, metformin has been documented to upregulate longevity-associated phenotypes [311] and extend lifespan in multiple organisms [307,312–315].

Metformin mediates levels of cytokines linked with inflammation [316–318], increases insulin sensitivity [319], and decreases IGF-1 levels [320] (Table 3). This cytokine mediation has been linked to the pro-longevity FOXO3a and the activator protein (AP)-1 transcription factor pathway, both of which can regulate cytokine levels. Interestingly, the ATF2 network was also enriched in response to metformin in human fibroblasts [316], indicating metformin may also function to mimic AAR; therefore, working via multiple pathways to promote longevity. Although cytokine–cytokine receptor signaling was also previously identified in response to rapamycin treatment in normal human fibroblasts, meta-analyses comparing metformin and rapamycin in the same cell line identified divergent transcriptomes [220,316], suggesting that this alteration in cytokine signaling is a downstream impact of these compounds to promote health and lifespan, as opposed to key mechanisms driving response to these proposed CRMs.

Similar to CR, metformin decreases levels of p53, likely via AMPK-induced activation of SIRT1 function [298]. CR and metformin have common physiological impacts; for example, obese mice under CR and treated with metformin exhibit mitophagy and reduced oxidative stress [298]. Notably, expression of ER stress markers (such as ATF6 and X-box binding protein 1 (XBP-1)) were also decreased. XBP1 has been proposed as a transcription factor for regulating changes in gene expression to CR, whereas ATF6 is linked to the ISR in response to AAR and attenuating global protein translation to counteract cellular stressors. Song et al. [298] also demonstrated that Parkin, a tumor suppressor protein involved in mitophagy, was translocated to the mitochondria in response to CR and metformin in obese mice, inducing autophagy, indicating that both antiaging treatments can lead to the same results albeit by different paths. More research is needed to determine the similarities between metformin and CR mechanisms, at the transcriptomic and epigenomic levels; however, it is unlikely that this compound directly mimics CR.

6. Conclusions

Since discovering the ability of CR to extend the lifespan of rodents, research into CR and CRMs has increased exponentially. In parallel, investigations into the basis of aging have also increased, demonstrating the link between getting older and numerous pathologies (cancer, CVD, T2D, ND). As a result, a plethora of research now demonstrates the ability of CR and CRMs to promote longevity and decrease incidence/delay age-linked diseases. Moreover, it is now clear that CR and various CRMs are able to delay/reverse molecular mechanisms associated with aging processes; however, some CR/CRMs are better at delaying/reversing specific age-linked effects than others. For example, CR and metformin consistently decrease IGF-1 levels and increase insulin sensitivity, whereas resveratrol acts more frequently to promote antioxidant pathways. The complexity of feedback signaling at the cellular and organismal levels indicates that to further pursue mechanisms in promoting longevity, it will be important to consider these effects in future experiments, with current data likely exhibiting controversy due to the lack of the elucidation of feedback loops and time required for these to take effect.
As whole-transcriptome profiling becomes more widely used, the availability of data regarding the impact of CR, AAR, and CRMs on the genome also increases. These data are beginning to reveal that it is unlikely any of these interventions directly mimic one another, but instead implement divergent mechanisms to arrive at the same endpoint, even when considering the usual factors underlying data variation (species, tissue type, dosage, time). As such, it is important that in the future, researchers are cautious of terminology, and perhaps it is timely to propose that this long-established class of supposed CRMs be referred to as longevity-promoting interventions (LPIs): diets, regimes, and compounds that function to achieve the same goal, health, and lifespan extension, but may do so in divergent manners. Finally, it is well established that CR, AAR, and CRMs (those discussed here, as well as others) extend health and lifespan. Although decreased mTOR function is often used as the benchmark for this, new findings, in part derived from whole-transcriptome analyses, enable the identification of other pathways that may exert influence. Moving forward, examining the crosstalk among these pathways will advance understanding of how to promote healthy aging.

**Funding:** We would like to acknowledge the funding agencies that helped support the individuals involved in the production of this manuscript. C.A.-P. is supported by a scholarship provided by the College of Graduate and Postdoctoral Studies (U of S). D.D.M. is the Saskatchewan Research Chair in Alzheimer Disease and Related Dementias funded by the Alzheimer Society of Saskatchewan and the Saskatchewan Health Research Foundation. C.H.E. is supported through Natural Sciences and Engineering Council of Canada (NSERC) and the Canadian Institutes of Health Research (CIHR) funding. Z.E.G. is supported by a Vanier Canada Graduate Scholarship.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

| Acronym | Description |
|---------|-------------|
| AAR | Amino acid restriction |
| AARE | Amino acid response element |
| AD | Alzheimer’s disease |
| ADAM10 | Disintegrin and metalloproteinase domain-containing protein 10 |
| AP-1 | Activator protein 1 |
| APP | Amyloid precursor protein |
| AKT | Protein Kinase B |
| AMP | Adenosine monophosphate |
| AMPK | Adenosine monophosphate kinase |
| ARE | Antioxidant response elements |
| Arf-1 GTPase | ADP ribosylation factor |
| α-SMA | Alpha smooth muscle actin |
| ATF | Activating transcription factor |
| ATG | Autophagy-related genes |
| ATP | Adenosine triphosphate |
| AZF1P | Nuclear-localized zinc-finger |
| BACE | Beta-secretase 1 |
| BAT | Brown adipose tissue |
| BCAA | Branched-chain amino acids |
| BCL-2 | B-cell lymphoma 2 |
| BCL-XL | B-cell lymphoma-extra-large |
| BDNF | Brain-derived neurotrophic factor |
| CA-9 | Carbonic anhydrase 9 |
| CamKKB | Calcium/calmodulin-dependent protein kinase kinase B |
| CASTOR | Cytosolic arginine sensor for mTORC1 |
| CAT | Catalase |
| CCL3 | Chemokine (C-C motif) ligand 3 |
| Cpsf6 | Cleavage and polyadenylation specific factor 6 |
| CK19 | Cytokeratin-19 |
| Abbreviation | Full Name |
|--------------|-----------|
| CR           | Caloric restriction |
| CRMs         | Caloric restriction mimetic |
| CVD          | Cardiovascular disease |
| CYP1         | Cytochrome P450 |
| DMTF         | Drosophila metal-responsive transcription factor |
| eIF2         | Eukaryotic initiation factor 2 |
| ER           | Endoplasmic reticulum |
| FGF21        | Fibroblast growth factor 21 |
| FOXO3a       | Forkhead box O3a |
| GADD34       | Growth arrest and DNA damage-inducible protein 34 |
| GATOR        | GTPase-activating protein toward rags |
| GCN2         | General control nonderepressible 2 |
| GDP          | Guanosine diphosphate |
| GHS          | Glycinyl-histidinyl-serine |
| GLUT1        | Glucose transporter 1 |
| GREB1        | Growth-regulating estrogen receptor binding 1 |
| GSK-3β       | Glycogen synthase kinase-3β |
| GTP          | Guanosine triphosphate |
| HGPS         | Hutchinson–Gilford progeria syndrome |
| HIF1α        | Hypoxia-inducible factor-1α |
| HSF1P        | Heat shock factor |
| IGF-1        | Insulin-like growth factor-1 |
| IL           | Interleukin |
| IRS-1        | Insulin receptor substrate 1 |
| ISR          | Integrated stress response |
| JNK          | C-jun N-terminal kinase |
| LKB1         | Liver kinase B1 |
| LMX1b        | LIM homeobox transcription factor 1-β |
| MAPK         | Mitogen activator protein kinase |
| MEF3         | Mitochondrial editing factor 3 |
| MMP9         | Matrix metallopeptidase 9 |
| Mt           | Metallothionein |
| mTOR         | Mammalian target of rapamycin |
| mTORC1       | Mammalian target of rapamycin complex 1 |
| mTORC2       | Mammalian target of rapamycin complex 2 |
| NAD+         | Nicotinamide adenine dinucleotide |
| NAM          | Nicotinamide |
| ND           | Neurodegenerative diseases |
| NF-κB        | Nuclear factor-κB |
| NFκbA        | NFκB inhibitor α |
| NRF2         | Nuclear receptor factor 2 |
| Fax6         | Paired box 6 |
| PDK1         | 3-phosphoinositide-dependent protein kinase 1 |
| PGC-1α       | Peroxisome proliferator-activated receptor gamma coactivator-1α |
| PI3K         | Phosphoinositide 3-kinase |
| Pitx2        | pituitary homeobox 2 |
| PRDM14       | PR domain zinc finger protein 14 |
| RagA/B       | Ras-related GTP-binding protein A and B |
| RagC/D       | ras-related GTP-binding protein C and D |
| Rheb         | RAS homolog enriched in brain |
| ROS          | Reactive oxygen species |
| S6K1         | Ribosomal protein S6 kinase |
| SAAR         | Sulfur amino acid restriction |
| SAM          | S-adenosyl-methionine |
SAMTOR  SAM sensor upstream of mTORC1  
Sfpq  Splicing factor proline and glutamine rich  
Sfrs  Serine- and arginine-rich splicing factor  
SIRT1  Sirtuin 1  
SOD  Superoxide dismutase  
SPD  Starvation pseudodiabetes  
STAT3  Signal transducer and activator of transcription 3  
STAT5A/B  Signal transducer and activator of transcription 5A/B  
T2D  Type 2 diabetes  
Timp3  Metalloproteinase inhibitor 3  
TNFx  Tumor necrosis factor-α  
TSC  Tuberous sclerosis complex  
Txnip  Thioredoxin interacting protein  
ULK1  Unc-51 Like Autophagy Activating Kinase 1  
VEGFR  Vascular endothelial growth factor receptor  
WAT  White adipose tissue  
WNT  Wingless-related integration site  
XBP-1  X-box-binding protein 1  
YBX1  Y-Box 1  
Zbt16  Zinc finger and BTB domain-containing protein 16  
Zscan1  Zinc finger and SCAN domain-containing 1  

References
1. Seals, D.R.; Jablonski, K.L.; Donato, A.J. Aging and vascular endothelial function in humans. Clin. Sci. 2011, 120, 357–375. [CrossRef]  
2. Del Zoppo, G.J. Aging and the neurovascular unit. Ann. N. Y. Acad. Sci. 2012, 1268, 127–133. [CrossRef] [PubMed]  
3. Chung, H.Y.; Cesari, M.; Anton, S.; Marzetti, E.; Giovannini, S.; Seo, A.Y.; Carter, C.; Yu, B.P.; Leeuwenburgh, C. Molecular inflammation: Underpinnings of aging and age-related diseases. Ageing Res. Rev. 2009, 8, 18–30. [CrossRef] [PubMed]  
4. Ahima, R.S. Connecting obesity, aging and diabetes. Nat. Med. 2009, 15, 996–997. [CrossRef]  
5. McCay, C.M.; Crowell, M.F.; Maynard, L.A. The effect of retarded growth upon the length of life span and upon the ultimate body size. J. Nutr. 1935, 10, 63–79. [CrossRef]  
6. Mattison, J.A.; Colman, R.J.; Beasley, T.M.; Allison, D.B.; Kemnitz, J.W.; Roth, G.S.; Ingram, D.K.; Weindruch, R.; De Cabo, R.; Anderson, R.M. Caloric restriction improves health and survival of rhesus monkeys. Nat. Commun. 2017, 8, 14063. [CrossRef]  
7. Mattison, J.A.; Roth, G.S.; Beasley, T.M.; Tilmont, E.M.; Handy, A.M.; Herbert, R.L.; Longo, D.L.; Allison, D.B.; Young, J.E.; Bryant, M.; et al. Impact of caloric restriction on health and survival in rhesus monkeys from the nia study. Nature 2012, 489, 318–321. [CrossRef] [PubMed]  
8. Colman, R.J.; Beasley, T.M.; Kemnitz, J.W.; Johnson, S.C.; Weindruch, R.; Anderson, R.M. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat. Commun. 2014, 5, 1–5. [CrossRef] [PubMed]  
9. Jiang, J.C.; Jaruga, E.; Repnevskaya, M.V.; Jazwinski, S.M. An intervention resembling caloric restriction prolongs life span and retards aging in yeast. FASEB J. 2000, 14, 2135–2137. [CrossRef]  
10. Brandhorst, S.; Choi, I.Y.; Wei, M.; Cheng, C.W.; Sedrakyan, S.; Navarrete, G.; Dubeau, L.; Yap, L.P.; Park, R.; Vinciguerra, M.; et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 2015, 22, 86–99. [CrossRef]  
11. Mercken, E.M.; Crosby, S.D.; Lamming, D.W.; JeBailey, L.; Krzysikwalker, S.M.; Villareal, D.T.; Capri, M.; Franceschi, C.; Zhang, Y.; Becker, K.G.; et al. Calorie restriction in humans inhibits the p38/akt pathway and induces a younger transcription profile. Aging Cell 2013, 12, 645–651. [CrossRef] [PubMed]  
12. Mirzaei, H.; Suarez, J.A.; Longo, V.D. Protein and amino acid restriction, aging and disease: From yeast to humans. Trends Endocrinol. Metab. TEM 2014, 25, 558–566. [CrossRef] [PubMed]
13. Jewell, J.L.; Russell, R.C.; Guan, K.L. Amino acid signalling upstream of mtor. Nat. Rev. Mol. Cell Biol. 2013, 14, 133–139. [CrossRef] [PubMed]

14. Unnikrishnan, A.; Kurup, K.; Salmon, A.B.; Richardson, A. Is rapamycin a dietary restriction mimetic? J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2020, 75, 4–13. [CrossRef]

15. Lamming, D.W.; Ye, L.; Sabatini, D.M.; Baur, J.A. Rapalogs and mtor inhibitors as anti-aging therapeutics. J. Clin. Investig. 2013, 123, 980–989. [CrossRef]

16. Li, J.; Zhang, C.; Liu, Y.-M.; Chen, K.-L.; Chen, G. A comparative study of anti-aging properties and mechanism: Resveratrol and caloric restriction. Oncotarget 2017, 8, 65717–65729. [CrossRef]

17. Chung, J.H.; Manganiello, V.; Dyck, J.R. Resveratrol as a calorie restriction mimetic: Therapeutic implications. Trends Cell Biol. 2012, 22, 546–554. [CrossRef]

18. Moucheirod, L.; Molin, L.; Dalliere, N.; Solari, F. Life span extension by resveratrol, rapamycin, and metformin: The promise of dietary restriction mimetics for an healthy aging. BioFactors 2010, 36, 377–382. [CrossRef]

19. Onken, B.; Driscoll, M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend c. elegans healthspan via ampk, lkb1, and skn-1. PLoS ONE 2010, 5, 1–13. [CrossRef]

20. Walaszczyk, A.; Dookun, E.; Redgrave, R.; Tual-Chalot, S.; Victorelli, S.; Spyridopoulos, I.; Owens, A.; Arthur, H.M.; Passos, J.F.; Richardson, G.D. Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction. Aging Cell 2019, 18, e12945. [CrossRef]

21. Baar, M.P.; Brandt, R.M.C.; Putavet, D.A.; Klein, J.D.; Derks, K.W.; Bourgeois, B.R.; Stryeck, S.; Rijksen, Y.; van Willigenburg, H.; Feijtel, D.A.; et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 2017, 169, 132–147.e116. [CrossRef] [PubMed]

22. Baker, D.J.; Wijschate, T.; Tchkonia, T.; Lebrasseur, N.K.; Childs, B.G.; Van De Sluis, B.; Kirkland, J.L.; Van Deursen, J.M. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nat. Cell Biol. 2011, 47, 232–236. [CrossRef] [PubMed]

23. Aunan, J.R.; Watson, M.M.; Hagland, H.R.; Soreide, K. Molecular and biological hallmarks of ageing. Br. J. Sci. 2016, 103, e29–e46. [CrossRef] [PubMed]

24. Csiszar, A.; Labinskyy, N.; Jiménez, R.; Pinto, J.T.; Wallahb, P.; Losonczy, G.; Pearson, K.J.; De Cabo, R.; Ungvari, Z. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: Role of circulating factors and sirt1. Mech. Ageing Dev. 2009, 130, 518–527. [CrossRef] [PubMed]

25. Mair, W.; Morante, I.; Rodrigues, A.P.C.; Manning, G.; Montminy, M.; Shaw, R.J.; Dillin, A. Lifespan extension induced by ampk and calcineurin is mediated by crtc-1 and creb. Nature 2011, 470, 404–408. [CrossRef] [PubMed]

26. Lakowski, B.; Hekimi, S. The genetics of caloric restriction in caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 1998, 95, 13091–13096. [CrossRef] [PubMed]

27. Ingle, L.; Wood, T.R.; Banta, A.M. A study of longevity, growth, reproduction and heart rate in daphnia longispina as influenced by limitations in quantity of food. J. Exp. Zool. 1937, 76, 325–353. [CrossRef] [PubMed]

28. Weeks, S.C. Effects of dietary restriction on lifespan, growth, and reproduction of the clam shrimp eulimnadia texana. Hydrobiologia 2020, 847, 3067–3076. [CrossRef]

29. Austad, S.N. Life extension by dietary restriction in the bowl and doily spider, frontinella pyramitela. Exp. Gerontol. 1989, 24, 83–92. [CrossRef]

30. Weindruch, R.; Walford, R.L.; Fligiel, S.; Guthrie, D. The retardation of aging in mice by dietary restriction: Longevity, cancer, immunity and lifetime energy intake. J. Nutr. 1986, 116, 641–654. [CrossRef]

31. Colman, R.J.; Anderson, R.M.; Johnson, S.C.; Kastman, E.K.; Kosmatka, K.J.; Beasley, T.M.; Allison, D.B.; Cruzen, C.; Simmons, H.A.; Kemnitz, J.W.; et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325, 201–204. [CrossRef] [PubMed]

32. Yegorov, Y.E. Healthy aging: Antioxidants, uncouplers and/or telomerase? Mol. Biol. 2020, 54, 311–316. [CrossRef]

33. Barja, G. Towards a unified mechanistic theory of aging. Exp. Gerontol. 2019, 124, 110627. [CrossRef]

34. Hambly, C.; Speakman, J.R. Contribution of different mechanisms to compensation for energy restriction in the mouse. Obes. Res. 2005, 13, 1548–1557. [CrossRef] [PubMed]
35. Blanc, S.; Schoeller, D.; Kemnitz, J.; Weindruch, R.; Colman, R.; Newton, W.; Wink, K.; Baum, S.; Ramsey, J. Energy expenditure of rhesus monkeys subjected to 11 years of dietary restriction. J. Clin. Endocrinol. Metab. 2003, 88, 16–23. [CrossRef] [PubMed]

36. Cabelo, D.C.; Yanamadala, S.; Raffoul, J.J.; Guo, Z.; Soofi, A.; Heydari, A.R. Caloric restriction promotes genomic stability by induction of base excision repair and reversal of its age-related decline. DNA Repair 2003, 2, 295–307. [CrossRef]

37. Um, J.H.; Kim, S.J.; Kim, D.W.; Ha, M.Y.; Jang, J.H.; Chung, B.S.; Kang, C.D.; Kim, S.H. Tissue-specific changes of DNA repair protein ku and mthsp70 in aging rats and their retardation by caloric restriction. Mech. Ageing Dev. 2003, 124, 967–975. [CrossRef]

38. Vermeij, W.P.; Dollé, M.E.T.; Reiling, E.; Jaarsma, D.; Payan-Gomez, C.; Bombardieri, C.R.; Wu, H.; Roks, H.W.A.J.M.; Botter, S.M.; Van Der Erden, B.C.; et al. Restricted diet delays accelerated ageing and genomic stress in DNA-repair-deficient mice. Nature 2016, 537, 427–431. [CrossRef]

39. Ke, Z.; Firsanov, D.; Spencer, B.; Seluanov, A.; Gorbunova, V. Short-term calorie restriction enhances DNA repair by non-homologous end joining in mice. NPG Aging Mech. Dis. 2020, 6, 9. [CrossRef]

40. Wang, W.; Cai, G.; Chen, X. Dietary restriction delays the secretion of senescence associated secretory phenotype by reducing DNA damage response in the process of renal aging. Exp. Gerontol. 2018, 107, 4–10. [CrossRef]

41. Il’yasova, D.; Fontana, L.; Bhapkar, M.; Pieper, C.F.; Spasojevic, I.; Redman, L.M.; Das, S.K.; Huffman, K.M.; Kraus, W.E.; CALERIE Study Investigators. Effects of 2 years of caloric restriction on oxidative status assessed by urinary f2-isoprostanes: The calerie 2 randomized clinical trial. Aging Cell 2018, 17. [CrossRef] [PubMed]

42. Redman, L.M.; Smith, S.R.; Burton, J.H.; Martin, C.K.; Il’yasova, D.; Ravussin, E. Metabolic slowing and reduced oxidative damage with sustained caloric restriction support the rate of living and oxidative damage theories of aging. Cell Metab. 2018, 27, 805–815. [CrossRef] [PubMed]

43. Heilbronn, L.K.; De Jonge, L.; Frisard, M.I.; DeLany, J.P.; Larson-Meyer, D.E.; Rood, J.; Nguyen, T.; Martin, C.K.; Volaufova, J.; Most, M.M.; et al. Effect of 6-month caloric restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: A randomized controlled trial. JAMA 2006, 295, 1539–1548. [CrossRef]

44. Miwa, S.; Riyahi, K.; Partridge, L.; Brand, M.D. Lack of Correlation between Mitochondrial Reactive Oxygen Species Production and Life Span in Drosophila. Ann. N. Y. Acad. Sci. 2004, 1019, 388–391. [CrossRef] [PubMed]

45. Kabil, H.; Partridge, L.; Harshman, L.G. Superoxide dismutase activities in long-lived Drosophila melanogaster females: Chico 1 genotypes and dietary dilution. Biogerontology 2007, 8, 201–208. [CrossRef] [PubMed]

46. Wei, M.L.; Duan, P.; Wang, Z.-M.; Ding, M.; Tu, P. High glucose and high insulin conditions promote MCF-7 cell proliferation and invasion by upregulating IRS1 and activating the Ras/Raf/ERK pathway. Mol. Med. Rep. 2017, 16, 6690–6696. [CrossRef]

47. Ito, M.; Makino, N.; Matsuda, A.; Ikeda, Y.; Kakizaki, Y.; Saito, Y.; Ueno, Y.; Kawata, S. High Glucose Accelerates Cell Proliferation and Increases the Secretion and mRNA Expression of Osteopontin in Human Pancreatic Duct Epithelial Cells. Int. J. Mol. Sci. 2017, 18, 807. [CrossRef]

48. Kannan, K.; Fridell, Y.-W.C. Functional implications of Drosophila insulin-like peptides in metabolism, aging, and dietary restriction. Front. Physiol. 2013, 4, 288. [CrossRef]

49. Zhang, J.; Liu, F. Tissue-specific insulin signaling in the regulation of metabolism and aging. IUBMB Life 2014, 66, 485–495. [CrossRef]

50. Dao, M.C.; Sokolovska, N.; Brazeilles, R.; Affeldt, S.; Pelloux, V.; Prifti, E.; Chiloux, J.; Verger, E.O.; Kayser, B.D.; Aron-Wisnewskyj, J.; et al. A Data Integration Multi-Omics Approach to Study Calorie Restriction-Induced Changes in Insulin Sensitivity. Front. Physiol. 2019, 9. [CrossRef]

51. Granado, M.; Amor, S.; Martín-Carro, B.; Guerra-Menéndez, L.; Tejera-Muñoz, A.; González-Hedström, D.; Rubio, C.; Carrascosa, J.M.; García-Villañón, Á.L. Caloric restriction attenuates aging-induced cardiac insulin resistance in male Wistar rats through activation of PI3K/Akt pathway. Nutr. Metab. Cardiovasc. Dis. 2019, 29, 97–105. [CrossRef] [PubMed]

52. Mitchell, S.J.; Madrigal-Matute, J.; Scheibye-Knudsen, M.; Fang, E.; Aon, M.; González-Reyes, J.A.; Cortassa, S.; Kaushik, S.; González-Freire, M.; Patel, B.; et al. Effects of Sex, Strain, and Energy Intake on Hallmarks of Aging in Mice. Cell Metab. 2016, 23, 1093–1112. [CrossRef] [PubMed]
53. Fontana, L.; Villareal, D.T.; Das, S.K.; Smith, S.R.; Meydani, S.N.; Pittas, A.G.; Klein, S.; Bhapkar, M.V.; Rochon, J.; Ravussin, E.; et al. Effects of 2-year calorie restriction on circulating levels of IGF-1, IGF-binding proteins and cortisol in nonobese men and women: A randomized clinical trial. *Aging Cell* **2016**, *15*, 22–27. [CrossRef] [PubMed]

54. Fontana, L.; Weiss, E.P.; Villareal, D.T.; Klein, S.; Holloszy, J.O. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. *Aging Cell* **2008**, *7*, 681–687. [CrossRef] [PubMed]

55. Belsky, D.W.; Huffman, K.M.; Pieper, C.F.; Shalev, I.; Kraus, W.E. Change in the Rate of Biological Aging in Response to Caloric Restriction: CALERIE Biobank Analysis. *J. Gerontol. Ser. A Biol. Sci. Med Sci.* **2018**, *73*, 4–10. [CrossRef]

56. Rattan, S.I. Hormesis in aging. *Aging Res. Rev.* **2008**, *7*, 63–78. [CrossRef]

57. Calabrese, V.; Cornelius, C.; Cuzzocrea, S.; Iavicoli, I.; Rizzarelli, E.; Calabrese, E.J. Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity. *Mol. Asp. Med.* **2011**, *32*, 279–304. [CrossRef]

58. Matai, L.; Sarkar, G.C.; Chamoli, M.; Malik, Y.; Kumar, S.S.; Rautela, U.; Jana, N.R.; Chakrabarty, K.; Mukhopadhyay, A. Dietary restriction improves proteostasis and increases life span through endoplasmic reticulum hormesis. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 17383–17392. [CrossRef]

59. Santoro, A.; Martucci, M.; Conte, M.; Capri, M.; Franceschi, C.; Salvioi, S. Inflammaging, hormesis and the rationale for anti-aging strategies. *Aging Res. Rev.* **2020**, *64*, 101142. [CrossRef]

60. Kim, J.; Guan, K.-L. mTOR as a central hub of nutrient signalling and cell growth. *Nat. Cell Biol.* **2019**, *21*, 63–71. [CrossRef]

61. Kazyken, D.; Magnuson, B.; Bodur, C.; Acosta-Jaquez, H.A.; Zhang, D.; Tong, X.; Barnes, T.M.; Steinl, G.K.; Patterson, N.E.; Altheim, C.H.; et al. Ampk directly activates mtorc2 to promote cell survival during acute energetic stress. *Sci. Signal.* **2019**, *12*, eaav3249. [CrossRef]

62. Dibble, C.C.; Elis, W.; Menon, S.; Menon, S.; Qin, W.; Klekota, J.; Asara, J.M.; Finan, P.M.; Kwiatkowski, D.J.; Murphy, L.O.; et al. Tbc1d7 is a third subunit of the tsc1-tsc2 complex upstream of mtorc1. *Mol. Cell.* **2012**, *47*, 535–546. [CrossRef]

63. Menon, S.; Dibble, C.C.; Talbott, G.; Hoxhaj, G.; Valvezan, A.J.; Takahashi, H.; Cantley, L.C.; Manning, B.D. Spatial control of the tsc complex integrates insulin and nutrient regulation of mtorc1 at the lysosome. *Cell* **2014**, *156*, 771–785. [CrossRef] [PubMed]

64. Liu, G.Y.; Sabatini, D.M. Mtor as the nexus of nutrition, growth, ageing and disease. *Nat. Rev. Mol. Cell Biol.* **2020**, *21*, 183–203. [CrossRef]

65. Saxon, R.A.; Sabatini, D.M. Mtor signaling in growth, metabolism, and disease. *Cell* **2017**, *168*, 960–976. [CrossRef] [PubMed]

66. Brugarolas, J.; Lei, K.; Hurley, R.L.; Manning, B.D.; Reiling, J.H.; Hafen, E.; Witters, L.A.; Ellisen, L.W.; Kaelin, W.G., Jr. Regulation of mtor function in response to hypoxia by redd1 and the tsc1/tsc2 tumor suppressor complex. *Genes Dev.* **2004**, *18*, 2893–2904. [CrossRef] [PubMed]

67. Inoki, K.; Li, Y.; Xu, T.; Guan, K.-L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. *Genes Dev.* **2003**, *17*, 1829–1834. [CrossRef] [PubMed]

68. B’Chir, W.; Maurin, A.C.; Carraro, V.; Averous, J.; Jousse, C.; Muranishi, Y.; Parry, L.; Stepien, G.; Lafourmioux, P.; Bruhat, A. The eif2alpha/atf4 pathway is essential for stress-induced autophagy gene expression. *Nucleic Acids Res.* **2013**, *41*, 7683–7699. [CrossRef]

69. Cohen, H.Y.; Miller, C.; Bitterman, K.J.; Wall, N.R.; Hecking, B.; Kessler, B.; Howitz, K.T.; Gorospe, M.; De Cabo, R.; Sinclair, D.A. Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase. *Science* **2004**, *305*, 390–392. [CrossRef]

70. Nemoto, S.; Fergusson, M.M.; Finkel, T. Nutrient availability regulates sirt1 through a forkhead-dependent pathway. *Science* **2004**, *306*, 2105–2108. [CrossRef]

71. Canto, C.; Gerhart-Hines, Z.; Feige, J.N.; Lagouge, M.; Noriega, L.; Milne, J.C.; Elliott, P.J.; Puigserver, P.; Auwerx, J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. *Nature* **2009**, *458*, 1056–1060. [CrossRef] [PubMed]

72. Woods, A.; Johnstone, S.R.; Dickerson, K.; Leiper, F.C.; Fryer, L.G.; Neumann, D.; Schlattner, U.; Wallimann, T.; Carlson, M.; Carling, D. LKB1 Is the Upstream Kinase in the AMP-Activated Protein Kinase Cascade. *Curr. Biol.* **2003**, *13*, 2004–2008. [CrossRef] [PubMed]
94. Yang, L.; Licastro, D.; Cava, E.; Veronese, N.; Spelta, F.; Rizza, W.; Bertozzi, B.; Villereal, D.T.; Hotamisligil, G.S.; Holloszy, J.O.; et al. Long-term calorie restriction enhances cellular quality-control processes in human skeletal muscle. *Cell Rep.* **2016**, *14*, 422–428. [CrossRef]

95. Floress, J.G.; Schulte, R.; Tsai, H.H.; Tyagi, S.; Ibarra, A.; Shokhirev, M.N.; Huang, L.; Hetzer, M.W.; Davies, O.R.; Jaenisch, R.; et al. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. *J. Biol. Chem.* **2017**, *292*, 15395–15408. [CrossRef]

96. Afman, L.A. Dietary restriction and metabolic disease. *J. Nutr.* **2011**, *141*, 2418S–2422S. [CrossRef]

97. Ulu, Z.O.; Ulu, S.; Dogan, S.; Tuna, B.G.; Ozgenturk, N.O. Transcriptome analysis of the thymus in short-term calorie-restricted mice using RNA-seq. *Int. J. Genom.* **2018**, *2018*. [CrossRef]

98. Van Bussel, I.P.; Jolink-Stoppelenburg, A.; De Groot, L.C.P.G.M.; Müller, M.; Afman, L.A. Dietary restriction reprograms the Single-Cell Transcriptional Landscape of Rattus Norvegicus Aging. *Cell* **2020**, *180*, 984–1001.e22. [CrossRef] [PubMed]

99. Yang, L.; Licastro, D.; Cava, E.; Veronese, N.; Spelta, F.; Rizza, W.; Bertozzi, B.; Villereal, D.T.; Hotamisligil, G.S.; Holloszy, J.O.; et al. Long-term calorie restriction enhances cellular quality-control processes in human skeletal muscle. *Cell Rep.* **2016**, *14*, 422–428. [CrossRef]

100. Khan, S.S.; Singer, B.D.; Vaughan, D.E. Molecular and physiological manifestations and measurement of aging in humans. *Aging Cell* **2017**, *16*, 624–633. [CrossRef]

101. Hara, K.; Yonezawa, K.; Weng, Q.-P.; Kozlowski, M.T.; Belham, C.; Avruch, J. Amino Acid Starvation Regulated by Amino Acid Status of the Mammalian Target of Rapamycin Complex 1. *Genome Biol.* **2018**, *19*, 1–8. [CrossRef] [PubMed]

102. Whitaker, R.; Gil, M.P.; Ding, E.; Tatar, M.; Helfand, S.L.; Neretti, N. Dietary switch reveals fast coordinated gene expression changes in Drosophila melanogaster. *Aging* **2014**, *6*, 355–368. [CrossRef]

103. Fleischer, J.G.; Shokhirev, M.N.; Huang, L.; Hetzer, M.W.; Davies, O.R.; Jaenisch, R.; et al. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. *J. Biol. Chem.* **2017**, *292*, 15395–15408. [CrossRef]

104. Fleischer, J.G.; Schulte, R.; Tsai, H.H.; Tyagi, S.; Ibarra, A.; Shokhirev, M.N.; Huang, L.; Hetzer, M.W.; Navlakha, S. Predicting age from the transcriptome of human dermal fibroblasts. *Genome Biol.* **2018**, *19*, 1–8. [CrossRef] [PubMed]

105. Fleischer, J.G.; Schulte, R.; Tsai, H.H.; Tyagi, S.; Ibarra, A.; Shokhirev, M.N.; Huang, L.; Hetzer, M.W.; Navlakha, S. Predicting age from the transcriptome of human dermal fibroblasts. *Genome Biol.* **2018**, *19*, 1–8. [CrossRef] [PubMed]

106. Cao, S.X.; Dhahbi, J.M.; Mote, P.L.; Spindler, S.R. Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 10630–10635. [CrossRef] [PubMed]

107. Fleischer, J.G.; Schulte, R.; Tsai, H.H.; Tyagi, S.; Ibarra, A.; Shokhirev, M.N.; Huang, L.; Hetzer, M.W.; Davies, O.R.; Jaenisch, R.; et al. Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. *J. Biol. Chem.* **2017**, *292*, 15395–15408. [CrossRef]

108. Min, K.-J.; Tatar, M. Restriction of amino acids extends lifespan in *Drosophila melanogaster*. *Mech. Ageing Dev.* **2006**, *127*, 643–646. [CrossRef]

109. Xiao, F.; Yu, J.; Guo, Y.; Deng, J.; Li, K.; Du, Y.; Chen, S.; Zhu, J.; Sheng, H.; Guo, F. Effects of individual branched-chain amino acids deprivation on insulin sensitivity and glucose metabolism in mice. *Metabolism* **2014**, *63*, 841–850. [CrossRef] [PubMed]

110. Afman, L.A. Dietary restriction and metabolic disease. *J. Nutr.* **2011**, *141*, 2418S–2422S. [CrossRef]

111. Takenaka, A.; Oki, N.; Takahashi, S.-I.; Noguchi, T. Dietary Restriction of Single Essential Amino Acids Reduces Plasma Insulin-Like Growth Factor-I (IGF-I) but Does Not Affect Plasma IGF-Binding Protein-1 in Rats. *Am. Soc. Nutr. Sci.* **2000**, *130*, 2910–2914. [CrossRef] [PubMed]

112. Peng, W.; Robertson, L.; Gallinetti, J.; Mejia, P.; Vose, S.; Charlip, A.; Chu, T.; Mitchell, J.R. Surgical Stress Resistance Induced by Single Amino Acid Deprivation Requires Gen2 in Mice. *Sci. Transl. Med.* **2012**, *4*, 118ra11. [CrossRef] [PubMed]
Sanz, A.; Caro, P.; Ayala, V.; Portero-Otin, M.; Pamplona, R.; Barja, G. Methionine restriction decreases mitochondrial oxygen radical generation and leak as well as oxidative damage to mitochondrial DNA and proteins. *FASEB J.* 2006, 20, 1064–1073. [CrossRef]

Caro, P.; Gómez, J.; López-Torres, M.; Sánchez, I.; Naudi, A.; Jove, M.; Pamplona, R.; Barja, G. Forty percent and eighty percent methionine restriction decrease mitochondrial ROS generation and oxidative stress in rat liver. *Biogerontology* 2008, 9, 183–196. [CrossRef]

Castaño-Martínez, T.; Schumacher, F.; Schumacher, S.; Kochlik, B.; Weber, D.; Grune, T.; Biemann, R.; McCann, A.; Abraham, K.; Weikert, C.; et al. Methionine restriction prevents onset of type 2 diabetes in NZO mice. *FASEB J.* 2019, 33, 7092–7102. [CrossRef]

Bárcena, C.; López-Otin, C.; Kroemer, G. Methionine restriction for improving progeria: Another autophagy-inducing anti-aging strategy? *Autophagy* 2019, 15, 558–559. [CrossRef]

Bárcena, C.; Quiró, P.M.; Durand, S.; Mayoral, P.; Rodríguez, F.; Caravia, X.M.; Mariño, G.; Garabay, C.; Fernández-García, M.T.; Kroemer, G.; et al. Methionine Restriction Extends Lifespan in Progeroid Mice and Alters Lipid and Bile Acid Metabolism. *Cell Rep.* 2018, 24, 2392–2403. [CrossRef]

Zaborske, J.M.; Wu, X.; WEK, R.C.; Pan, T. Selective control of amino acid metabolism by the GCN2 eIF2 kinase pathway in Saccharomyces cerevisiae. *BMC Biochem.* 2010, 11, 29. [CrossRef]

Xiao, F.; Huang, Z.; Li, H.; Yu, J.; Wang, C.; Chen, S.; Meng, Q.; Cheng, Y.; Gao, X.; Li, J.; et al. Leucine Deprivation Increases Hepatic Insulin Sensitivity via GCN2/mTOR/S6K1 and AMPK Pathways. *Diabetes* 2011, 60, 746–756. [CrossRef]

Yu, L.; McPhee, C.K.; Zheng, L.; Mardones, G.A.; Rong, Y.; Peng, J.; Mi, N.; Zhao, Y.; Liu, Z.; Wan, F.; et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. *Nature* 2010, 465, 942–946. [PubMed]

Sancak, Y.; Bar-Peled, L.; Zoncu, R.; Markhard, A.L.; Nada, S.; Sabatini, D. Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids. *Cell* 2010, 141, 290–303. [CrossRef][PubMed]

Sancak, Y.; Peterson, T.R.; Shaul, Y.D.; Lindquist, R.A.; Thoreen, C.C.; Bar-Peled, L.; Sabatini, D. M. The Rag GTases Bind Raptor and Mediate Amino Acid Signaling to mtorc1. *Science* 2008, 320, 1496–1501. [CrossRef][PubMed]

Kim, E.; Goraksha-Hicks, P.; Li, L.; Neufeld, T.P.; Guan, K.-L. Regulation of TORC1 by Rag GTPases in nutrient response. *Nat. Cell Biol.* 2008, 10, 935–945. [CrossRef][PubMed]

Wolffson, R.L.; Chantranupong, L.; Wyant, G.A.; Gu, X.; Orozco, J.M.; Shen, K.; Condon, K.J.; Petri, S.; Kedir, J.; Scarra, S.M.; et al. KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1. *Nature* 2017, 543, 438–442. [CrossRef][PubMed]

Saxton, R.A.; Chantranupong, L.; Knockenhauer, K.E.; Schwartz, T.U.; Sabatini, T.M. Mechanism of arginine sensing by castor1 upstream of mtorc1. *Nature* 2016, 536, 229–233. [CrossRef][PubMed]

Saxton, R.A.; Knockenhauer, K.E.; Wolffson, R.L.; Chantranupong, L.; Pacold, M.E.; Wang, T.; Schwartz, T.U.; Sabatini, D. Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway. *Science* 2016, 351, 53–58. [CrossRef][PubMed]

Chantranupong, L.; Scarra, S.M.; Saxton, R.A.; Gygi, M.P.; Shen, K.; Wyant, G.A.; Wang, T.; Harper, J.W.; Gygi, S.P.; Sabatini, D.M. The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway. *Cell* 2016, 165, 153–164. [CrossRef][PubMed]

Chantranupong, L.; Wolffson, R.L.; Orozco, J.M.; Saxton, R.A.; Scarra, S.M.; Bar-Peled, L.; Spooner, E.; Isasa, M.; Gygi, S.P.; Sabatini, D.M. The Sestrins Interact with GATOR2 to Negatively Regulate the Amino-Acid-Sensing Pathway Upstream of mTORC1. *Cell Rep.* 2014, 9, 1–8. [CrossRef][PubMed]

Parmigiani, A.; Nourbakhsh, A.; Ding, B.; Wang, W.; Kim, Y.C.; Akopianis, K.; Guan, K.-L.; Karin, M.; Budanov, A.V. Sestrins Inhibit mTORC1 Kinase Activation through the GATOR Complex. *Cell Rep.* 2014, 9, 1281–1291. [CrossRef][PubMed]

Stracka, D.; Jozefczuk, S.; Rudloff, F.; Sauer, U.; Hall, M.N. Nitrogen Source Activates TOR (Target of Rapamycin) Complex 1 via Glutamine and Independently of Gtr/Rag Proteins. *J. Biol. Chem.* 2014, 289, 25010–25020. [CrossRef][PubMed]

Jewell, J.L.; Kim, Y.C.; Russell, R.C.; Yu, F.-X.; Park, H.W.; Plouffe, S.W.; Tagliabucci, V.S.; Guan, K.-L. Differential regulation of mTORC1 by leucine and glutamine. *Science* 2015, 347, 194–198. [CrossRef][PubMed]
153. Durán, R.V.; Oppliger, W.; Robitaille, A.M.; Heiserich, L.; Skendaj, R.; Gottlieb, E.; Hall, M.N. Glutaminolysis activates rag-mtorc1 signaling. *Mol. Cell* 2012, 47, 349–358. [CrossRef] [PubMed]

154. Lee, Y.-Y.; Cevallos, R.C.; Jan, E. An Upstream Open Reading Frame Regulates Translation of GADD34 during Cellular Stress That Induces eIF2alpha Phosphorylation. *J. Biol. Chem.* 2009, 284, 6661–6673. [CrossRef]

155. Kilberg, M.S.; Balasubramanian, M.; Fu, L.; Shan, J. The Transcription Factor Network Associated With the Amino Acid Response in Mammalian Cells. *Adv. Nutr.* 2012, 3, 295–306. [CrossRef]

156. Novoa, I.; Zhang, Y.; Zeng, H.; Jungreis, R.; Harding, H.P.; Ron, D. Stress-induced gene expression requires programmed recovery from translational repression. *EMBO J.* 2003, 22, 1180–1187. [CrossRef]

157. Chaveroux, C.; Joussé, C.; Cherasse, Y.; Maurin, A.-C.; Parry, L.; Carraro, V.; Derijard, B.; Bruhat, A.; Fafournoux, P. Identification of a Novel Amino Acid Response Pathway Triggering ATF2 Phosphorylation in Mammals. *Mol. Cell. Biol.* 2009, 29, 6515–6526. [CrossRef]

158. Rousakis, A.; Vlassis, A.; Vlanti, A.; Patera, S.; Thireos, G.; Syntichaki, P. The general control nonrepressible-2 kinase mediates stress response and longevity induced by target of rapamycin inactivation inCaenorhabditis elegans. *Aging Cell* 2013, 12, 742–751. [CrossRef]

159. De Sousa-Coelho, A.L.; Marrero, P.F.; Haro, D. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. *Biochem. J.* 2012, 443, 165–171. [CrossRef]

160. Maruyama, R.; Shimizu, M.; Li, J.; Inoue, J.; Inoue, J.; Sato, R. Fibroblast growth factor 21 induction by activating transcription factor 4 is regulated through three amino acid response elements in its promoter region. *Biosci. Biotechnol. Biochem.* 2016, 80, 929–934. [CrossRef]

161. Lees, E.K.; Kröl, E.; Grant, L.; Shearer, K.; Wyse, C.; Moncur, E.; Bykowski, A.S.; Mody, N.; Gettys, T.W.; Delibegovic, M. Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21. *Aging Cell* 2014, 13, 817–827. [CrossRef] [PubMed]

162. Laeger, T.; Albarado, D.C.; Burke, S.J.; Troclair, L.; Hedgepeth, J.W.; Berthoud, H.-R.; Gettys, T.W.; Collier, J.J.; Münzberg, H.; Morrison, C.D. Metabolic Responses to Dietary Protein Restriction Require an Increase in FGF21 that Is Delayed by the Absence of GCN2. *Cell Rep.* 2016, 16, 707–716. [CrossRef] [PubMed]

163. Zhang, Y.; Xie, Y.; Berglund, E.D.; Coate, K.C.; He, T.T.; Katafuchi, T.; Xiao, G.; Potthof, M.J.; Wei, W.; Wan, Y., et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mouse. *eLife* 2012, 1, e00065. [CrossRef] [PubMed]

164. Yan, J.; Wang, J.; Huang, H.; Huang, Y.; Mi, T.; Zhang, C.; Zhang, L. Fibroblast growth factor 21 delayed endothelial replicative senescence and protected cells from h2o2-induced premature senescence through sirt1. *Am. J. Transl. Res.* 2017, 9, 4492–4501. [PubMed]

165. Hanks, L.J.; Gutiérrez, O.M.; Bamman, M.M.; Ashraf, A.; McCormick, K.L.; Casazza, K. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. *J. Clin. Transl. Endocrinol.* 2015, 2, 77–82. [CrossRef] [PubMed]

166. Fujii, N.; Uta, S.; Kobayashi, M.; Sato, T.; Okita, N.; Higami, Y. Impact of aging and caloric restriction on fibroblast growth factor 21 signaling in rat white adipose tissue. *Exp. Gerontol.* 2019, 118, 55–64. [CrossRef]

167. Villarroja, J.; Gallego-Escuredo, J.M.; Delgado-Ángel, A.; Cairo, M.; Moure, R.; Mateo, M.G.; Domingo, J.C.; Domingo, P.; Giralt, M.; Villarroja, F. Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue. *Aging Cell* 2018, 17, e12822. [CrossRef]

168. So, W.Y.; Cheng, Q.; Xu, A.; Lam, K.S.L.; Leung, P.S. Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice. *Cell Death Dis.* 2015, 6, e1707. [CrossRef]

169. Fisher, F.M.; Chui, P.C.; Antonellis, P.J.; Bina, H.A.; Kharitonov, A.; Flier, J.S.; Maratos-Flier, E. Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State. *Diabetes* 2010, 59, 2781–2789. [CrossRef]

170. Hale, C.; Men, M.M.; Stanislaus, S.; Chinookoswong, N.; Hager, T.; Wang, M.; Veéniain, M.M.; Xu, J. Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance. *Endocrinology* 2012, 153, 69–80. [CrossRef]

171. Opoku, Y.K.; Liu, Z.; Afrija, J.; Khosho, M.H.; Ren, G.; Li, D.-S. Therapeutic Role of Fibroblast Growth Factor 21 (FGF21) in the Amelioration of Chronic Diseases. *Int. J. Pept. Res. Ther.* 2019, 26, 107–119. [CrossRef]

172. Lee, D.V.; Li, D.; Yan, Q.; Zhu, Y.; Goodwin, B.; Calle, R.A.; Brenner, M.B.; Talukdar, S. Fibroblast Growth Factor 21 Improves Insulin Sensitivity and Synergizes with Insulin in Human Adipose Stem Cell-Derived (hASC) Adipocytes. *PLoS ONE* 2014, 9, e111767. [CrossRef] [PubMed]
173. Li, H.; Wu, G.; Fang, Q.; Zhang, M.; Hui, X.; Sheng, B.; Wu, L.; Bao, Y.; Li, P.; Xu, A.; et al. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nat. Commun. 2018, 9, 272. [CrossRef] [PubMed]

174. Minard, A.Y.; Tan, S.-X.; Yang, P.; Fazakerley, D.J.; Domanova, W.; Parker, B.L.; Humphrey, S.J.; Jothi, R.; Stöckli, J.; James, D.E. mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. Cell Rep. 2016, 17, 29–36. [CrossRef] [PubMed]

175. Martel, R.R.; Klicius, J.; Galet, S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 1976, 55, 48–51. [CrossRef] [PubMed]

176. Blagosklonny, M.V. Aging and Immortality: Quasi-Programmed Senescence and Its Pharmacologic Inhibition. Cell Cycle 2006, 5, 2087–2102. [CrossRef]

177. Heitman, J.; Movva, N.R.; Hall, M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991, 253, 905–909. [CrossRef]

178. Van Duyne, G.D.; Standaert, R.F.; Schreiber, S.L.; Clardy, J. Atomic structure of the rapamycin human immunophilin FKBP-12 complex. J. Am. Chem. Soc. 1991, 113, 7433–7434. [CrossRef]

179. Hay, N.; Sonenberg, N. Upstream and downstream of mtor. Genes Dev. 2004, 18, 1926–1945. [CrossRef]

180. Weichhart, T. mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review. Gerontology 2018, 64, 127–134. [CrossRef]

181. Jansova, D.; Koncicka, M.; Tetkova, A.; Cerna, R.; Malik, R.; Del Llano, E.; Kubelka, M.; Susor, A. Regulation of 4E-BP1 activity in the mammalian oocyte. Cell Cycle 2017, 16, 927–939. [CrossRef] [PubMed]

182. Alvers, A.L.; Fishwick, L.K.; Wood, M.S.; Hu, D.; Chung, H.S.; Jr, W.A.D.; Aris, J.P. Autophagy and amino acid homeostasis are required for chronological longevity in Saccharomyces cerevisiae. Aging Cell 2009, 8, 353–369. [CrossRef] [PubMed]

183. Su, Y.; Lu, J.; Gong, P.; Chen, X.; Liang, C.; Zhang, J. Rapamycin induces autophagy to alleviate acute kidney injury following cerebral ischemia and reperfusion via the mtorc1/atg13/ulk1 signaling pathway. Mol. Med. Rep. 2018, 18, 5445–5454. [CrossRef] [PubMed]

184. Hua, H.; Kong, Q.; Zhang, H.; Wang, J.; Luo, T.; Jiang, Y. Targeting mTOR for cancer therapy. J. Hematol. Oncol. 2019, 12, 1–19. [CrossRef] [PubMed]

185. Imrali, A.; Mao, X.; Yeste-Velasco, M.; Shamash, J.; Lu, Y. Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. Am. J. Cancer Res. 2016, 6, 1772–1784. [PubMed]

186. Karthik, G.-M.; Ma, R.; Lövrot, J.; Kis, L.L.; Lindh, C.; Blomquist, L.; Fredriksson, I.; Bergh, J.; Hartman, J. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. Cancer Lett. 2015, 367, 76–87. [CrossRef]

187. Gao, G.; Chen, W.; Yan, M.; Liu, J.; Luo, H.; Wang, C.; Yang, P. Rapamycin regulates the balance between cardiomyocyte apoptosis and autophagy in chronic heart failure by inhibiting mtor signaling. Int. J. Mol. Med. 2019, 45, 195–209. [CrossRef]

188. Quarles, E.; Basisty, N.; Chiao, Y.A.; Merrihew, G.; Gu, H.; Sweetwyne, M.T.; Fredrickson, J.; Nguyen, N.; Razumova, M.; Koooker, K.; et al. Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. Aging Cell 2020, 19, e13086. [CrossRef]

189. Bikkul, M.U.; Clements, C.S.; Godwin, L.S.; Goldberg, M.W.; Kill, I.R.; Bridger, J.M. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson–Gilford progeria syndrome fibroblasts. Biogerontology 2018, 19, 579–602. [CrossRef]

190. Graziotto, J.J.; Cao, K.; Collins, F.S.; Krainc, D. Rapamycin activates autophagy in hutchinson-gilford progeria syndrome: Implications for normal aging and age-dependent neurodegenerative disorders. Autophagy 2012, 8, 147–151. [CrossRef]

191. Kawakami, Y.; Hambright, W.S.; Takayama, K.; Mu, X.; Lu, A.; Cummins, J.H.; Matsumoto, T.; Yurube, T.; Kuroda, R.; Kurosaoka, M.; et al. Rapamycin Rescues Age-Related Changes in Muscle-Derived Stem/Progenitor Cells from Progeroid Mice. Mol. Ther. Methods Clin. Dev. 2019, 14, 64–76. [CrossRef] [PubMed]

192. Zheng, X.; Boyer, L.; Jin, M.; Kim, Y.; Fan, W.; Bardy, C.; Berggren, T.; Evans, R.M.; Gage, F.H.; Hunter, T. Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration. eLife 2016, 5, 5. [CrossRef] [PubMed]
193. Staats, K.A.; Hernandez, S.; Schönenfeldt, S.; Bento-Abreu, A.; Dooley, J.; Van Damme, P.; Liston, A.; Robberecht, W.; Bosch, L.V.D. Rapamycin increases survival in ALS mice lacking mature lymphocytes. *Mol. Neurodegener.* 2013, 8, 31. [CrossRef] [PubMed]

194. Wang, Y.; Ma, Q.; Ma, X.; Zhang, Z.; Liu, N.; Wang, M. Role of mammalian target of rapamycin signaling in autophagy and the neurodegenerative process using a senescence accelerated mouse-prone 8 model. *Exp. Ther. Med.* 2017, 14, 1051–1057. [CrossRef]

195. Kaehlerlein, M.; Galvan, V. Rapamycin and Alzheimer’s disease: Time for a clinical trial? *Sci. Transl. Med.* 2019, 11, eaar4289. [CrossRef]

196. Tramutola, A.; Lanzillotta, C.; Barone, E.; Arena, A.; Zuliani, I.; Mosca, L.; Blarzino, C.; Butterfield, D.A.; Perluigi, M.; Di Domenico, F. Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. *Transl. Neurodegener.* 2018, 7, 28. [CrossRef]

197. Caccamo, A.; Majumder, S.; Richardson, A.; Strong, R.; Oddo, S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: Effects on cognitive impairments. *J. Biol. Chem.* 2010, 285, 13107–13120. [CrossRef] [PubMed]

198. Pupyshev, A.B.; Korolenko, T.A.; Tikhonova, M.A. Effects and Mechanisms of Rapamycin Action on Experimental Neurodegeneration. *Neurochem. J.* 2018, 12, 347–358. [CrossRef]

199. Anisimov, V.N.; Yurova, M.N.; Antoch, M.P.; Blagosklonny, M.V. Rapamycin Extends Maximal Lifespan in Cancer-Prone Mice. *Am. J. Pathol.* 2010, 176, 2092–2097. [CrossRef]

200. Komarova, E.A.; Antoch, M.P.; Novototskaya, L.R.; Chernova, O.B.; Paszkiewicz, G.; Leontieva, O.V.; Blagosklonny, M.V.; Gudkov, A.V. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice. *Aging 2012*, 4, 709–714. [CrossRef]

201. Hebert, M.; Licursi, M.; Jensen, B.; Baker, A.; Milway, S.; Malsbury, C.; Grant, V.L.; Adamec, R.; Hirasawa, M.; Blundell, J. Single Rapamycin Administration Induces Prolonged Downward Shift in Defended Body Weight in Rats. *PLoS ONE 2014*, 9, e93691. [CrossRef] [PubMed]

202. Lee, J.Y.; Kennedy, B.K.; Liao, C.-Y. Mechanistic target of rapamycin signaling in mouse models of accelerated aging. *J. Gerontol. Ser. A Biol. Sci. Med Sci.* 2020, 75, 64–72. [CrossRef] [PubMed]

203. Khaire, R.V.; Kondratova, A.A.; Patel, S.; Dubrovsky, Y.; Wrobel, M.; Antoch, M.P.; Kondratov, R.V. BMAL1-dependent regulation of the mTOR signaling pathway delays aging. *Aging 2014*, 6, 48–57. [CrossRef] [PubMed]

204. Liao, C.-Y.; Anderson, S.S.; Chicoine, N.H.; Mayfield, J.R.; Academia, E.C.; Wilson, J.A.; Pongkietisak, C.; Thompson, M.A.; Lagmay, E.P.; Miller, D.M.; et al. Rapamycin Reverses Metabolic Deficits in Lamin A/C-Deficient Mice. *Cell Metab.* 2016, 17, 2542–2552. [CrossRef]

205. Cao, K.; Graziotto, J.J.; Blair, C.D.; Mazzulli, J.R.; Erdos, M.R.; Kraine, D.; Collins, E.S. Rapamycin Reverses Cellular Phenotypes and Enhances Mutant Protein Clearance in Hutchinson-Gilford Progeria Syndrome Cells. *Sci. Transl. Med.* 2011, 3, 89ra58. [CrossRef] [PubMed]

206. Melzi, R.; Maffi, P.; Nano, R.; Sordi, V.; Mercalli, A.; Scavini, M.; Secchi, A.; Bonifacio, E.; Piemonti, L. Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans. *Islets 2009*, 1, 42–49. [CrossRef]

207. Piemonti, L.; Maffi, P.; Monti, L.; Lampasona, V.; Perseghin, G.; Magistretti, P.; Secchi, A.; Bonifacio, E. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. *Diabetologia 2010*, 53, 433–439. [CrossRef]

208. Groth, C.G.; Bäckman, L.; Morales, J.M.; Calne, R.; Kreis, H.; Lang, P.; Touraine, J.L.; Claesson, K.; Campistol, J.M.; Durand, D.; et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. *Transplantation 1999*, 67, 1036–1042. [CrossRef]

209. Lamming, D.W. Inhibition of the mechanistic target of rapamycin (mTOR)-rapamycin and beyond. *Cold Spring Harb. Perspect. Med.* 2016, 6, a025924. [CrossRef]

210. Chung, C.L.; Lawrence, I.; Hoffman, M.; Elgindi, D.; Nadhan, K.; Potnis, M.; Jin, A.; Sershon, C.; Binnebose, R.; Lorenzini, A.; et al. Topical rapamycin reduces markers of senescence and aging in human skin: An exploratory, prospective, randomized trial. *GeroScience 2019*, 41, 861–869. [CrossRef]
221. Ciołczyk-Wierzbicka, D.; Gil, D.; Zarzycka, M.; Laidler, P. mTOR inhibitor everolimus reduces invasiveness.
218. Choi, K.-M.; Hong, S.-J.; Van Deursen, J.M.; Kim, S.; Kim, K.H.; Lee, C.-K. Caloric Restriction and Rapamycin
214. Blagosklonny, M.V. Fasting and rapamycin: Diabetes versus benevolent glucose intolerance.
212. Fok, W.C.Y.; Zhang, Y.; Salmon, A.B.; Bhattacharya, A.; Gunda, R.; Jones, D.; Ward, W.; Fisher, K.; Richardson, A.; Pérez, V.I. Short-Term Treatment With Rapamyci and Dietary Restriction Have Overlapping and Distinctive Effects in Young Mice. J. Gerontol. Ser. A Biol. Sci. Med Sci. 2013, 68, 108–116. [CrossRef] [PubMed]
213. Lamming, D.W.; Ye, L.; Katajisto, P.; Goncalves, M.D.; Saitoh, M.; Stevens, D.M.; Davis, J.G.; Salmon, A.B.; Richardson, A.; Ahima, R.S.; et al. Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity. Science 2012, 335, 1638–1643. [CrossRef] [PubMed]
211. Fok, W.C.; Bokov, A.; Gelfond, J.; Yu, Z.; Zhang, Y.; Doderer, M.; Chen, Y.; Richardson, A.; Pérez, V.I. Short-term rapamycin treatment in mice has few effects on the transcriptome of white adipose tissue compared to dietary restriction. Mech. Ageing Dev. 2014, 140, 23–29. [CrossRef]
212. Shivaswamy, V.; McClure, M.; Passer, J.; Frahm, C.; Oehsner, L.; Erickson, J.; Bennett, R.G.; Hamel, F.G.; Larsen, J.I. Hyperglycemia induced by tacrolimus and sirolimus is reversible in normal sprague–dawley rats. Endocrine 2010, 37, 489–496. [CrossRef]
210. Fok, W.C.; Livi, C.B.; Bokov, A.; Yu, Z.; Chen, Y.; Richardson, A.; Pérez, V.I. Combined treatment of rapamycin and dietary restriction has a larger effect on the transcriptome and metabolome off liver. Aging Cell 2014, 13, 311–319. [CrossRef]
209. Choi, K.-M.; Hong, S.-J.; Van Deursen, J.M.; Kim, S.; Kim, K.H.; Lee, C.-K. Caloric Restriction and Rapamycin Differentially Alter Energy Metabolism in Yeast. J. Gerontol. Ser. A Biol. Sci. Med Sci. 2017, 73, 29–38. [CrossRef]
208. Garcia, D.N.; Saccon, T.D.; Pradiee, J.; Rincón, J.A.A.; Andrade, K.R.S.; Rovani, M.T.; Mondadori, R.G.; Cruz, L.A.X.; Barros, C.C.; Masternak, M.M.; et al. Effect of caloric restriction and rapamycin on ovarian aging in mice. GenScience 2019, 41, 395–408. [CrossRef]
207. Gillespie, Z.E.; Mackay, K.; Sander, M.; Trost, B.; Dawicki, W.; Wickramarathna, A.; Gordon, J.; Eramian, M.; Kill, I.R.; Bridger, J.M.; et al. Rapamycin reduces fibroblast proliferation without causing quiescence and induces STAT5A/B-mediated cytokine production. Nucleus 2015, 6, 490–506. [CrossRef]
206. Cioczyk-Wierzbićka, D.; Gil, D.; Zarzycka, M.; Laidler, P. mTOR inhibitor everolimus reduces invasiveness of melanoma cells. Hum. Cell 2020, 33, 88–97. [CrossRef]
205. Cassano, T.; Magini, A.; Giovagnoli, S.; Polchi, A.; Calcagnini, S.; Pace, L.; Lavecchia, M.A.; Scuderi, C.; Bronzuoli, M.R.; Ruggeri, L.; et al. Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer’s disease. Exp. Neurol. 2019, 311, 88–105. [CrossRef] [PubMed]
204. Mannick, J.B.; Morris, M.; Hockey, H.-U.; Roma, G.; Beibel, M.; Kulmatycki, K.; Watkins, M.; Shavlakadze, T.; Zhou, W.; Quinn, D.; et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci. Transl. Med. 2018, 10, eaau1564. [CrossRef]
203. Nawroth, R.; Stellwagen, F.; Stoehr, R.; Hartmann, A.; Krause, B.J.; Gschwend, J.E.; Retz, M. S6k1 and 4e-bp1 are independent regulated and control cellular growth in bladder cancer. PLoS ONE 2011, 6, e27509. [CrossRef] [PubMed]
202. Johnston, S.R. Are we missing the mtor target in breast cancer? Breast Cancer Res. Treat. 2011, 128, 607–611. [CrossRef]
201. Shavlakadze, T.; Zhu, J.; Wang, S.; Zhou, W.; Morin, B.; Egerman, M.A.; Fan, L.; Wang, Y.; Iartchouk, O.; Meyer, A.; et al. Short-term Low-Dose mTORC1 Inhibition in Aged Rats Counter-Regulates Age-Related Gene Changes and Blocks Age-Related Kidney Pathology. J. Gerontol. Ser. A Biol. Sci. Med Sci. 2018, 73, 845–852. [CrossRef] [PubMed]
200. DuBose, A.J.; Lichtenstein, S.T.; Petrash, N.M.; Erdos, M.R.; Gordon, L.B.; Collins, F.S. Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts. Proc. Natl. Acad. Sci. USA 2018, 115, 4206–4211. [CrossRef]
199. Kirchner, G.I.; Meier-Widenbach, I.; Manns, M.P. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 2004, 43, 83–95. [CrossRef]
230. Kuo, C.-T.; Chen, C.-L.; Li, C.-C.; Huang, G.-S.; Ma, W.-Y.; Hsu, W.-F.; Lin, C.-H.; Lu, Y.-S.; Wo, A.M. Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models. *Sci. Rep.* 2019, 9, 1–11. [CrossRef]

231. Saran, U.; Fetti, M.; Dufour, J.-E.F. Cellular and molecular effects of the mTOR inhibitor everolimus. *Clin. Sci. (London)* 2015, 129, 895–914. [CrossRef] [PubMed]

232. Baselga, J.; Campone, M.; Piccart-Gebhart, M.; Burris, H.A.; Rugo, H.S.; Sahmoud, T.; Noguchi, S.; Grant, M.; Pritchard, K.I.; Lebrun, F.; et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. *N. Engl. J. Med.* 2012, 366, 520–529. [CrossRef] [PubMed]

233. Sabine, V.S.; Sims, A.H.; Macaskill, E.J.; Renshaw, L.; Thomas, J.S.; Dixon, J.M.; Bartlett, J.M.S. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. *Breast Cancer Res. Treat.* 2010, 122, 419–428. [CrossRef] [PubMed]

234. Yoshida, K.; Imamura, C.K.; Hara, K.; Mochizuki, M.; Kenmotsu, H. Efficacy of the mTOR inhibitor everolimus, a mammalian target of rapamycin inhibitor, ameliorates streptozotocin-induced learning and memory deficits via neurochemical alterations in male rats. *EXCLI J.* 2018, 17, 999–1017.

235. Yoshida, K.; Imamura, C.K.; Hara, K.; Mochizuki, M.; Kenmotsu, H. Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12). *Metabolomics* 2017, 13, 98. [CrossRef]

236. Fanoudi, S.; Hosseini, M.; Alavi, M.S.; Boroushaki, M.T.; Hosseini, A.; Sadeghnia, H.R. Everolimus, a mammalian target of rapamycin inhibitor, ameliorates streptozotocin-induced learning and memory deficits via neurochemical alterations in male rats. *EXCLI J.* 2018, 17, 999–1017.

237. Yoshida, K.; Imamura, C.K.; Hara, K.; Mochizuki, M.; Kenmotsu, H. Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12). *Metabolomics* 2017, 13, 98. [CrossRef]

238. Wall, M.; Poortinga, G.; Hannan, K.M.; Pearson, R.B.; Hannan, R.D.; McArthur, G.A. Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. *Blood* 2008, 112, 2305–2317. [CrossRef]

239. Jiménez, J.; Pulido, L.; Bellido, C.; Usero, D.; Tallón-Aguilar, L.; Moreno, J.; Artacho, G.; Diez-Canedo, J.; Gómez, L.; Bravo, M. Rescue Immunosuppression With Mammalian Target of Rapamycin Inhibitor Drugs in Liver Transplantation. *Transplant. Proc.* 2010, 42, 641–643. [CrossRef]

240. Volk, M.J.; Pugh, T.D.; Kim, M.; Frith, C.H.; Daynes, R.A.; Ershler, W.B.; Weindruch, R. Dietary restriction from middle age attenuates age-associated lymphoma development and interleukin 6 dysregulation in C57BL/6 mice. *Cancer Res.* 1994, 54, 3054–3061. [PubMed]

241. Yuan, J.; Minter-Dykhouse, K.; Lou, Z. c-Myc–SIRT1 feedback loop regulates cell growth and transformation. *J. Cell Biol.* 2009, 185, 203–211. [CrossRef] [PubMed]

242. Tameine, F.; Verginadis, I.I.; Leli, N.M.; Polte, C.; Conn, C.S.; Ojha, R.; Salinas, C.S.; Chinga, F.; Monroy, A.M.; Fu, W.; et al. ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. *Nat. Cell Biol.* 2019, 21, 889–899. [CrossRef]

243. Klümpen, H.-J.; Beijnen, J.H.; Gurney, H.; Schellens, J.H. Inhibitors of mTOR. *Oncologist* 2010, 15, 1262–1269. [CrossRef]

244. Schreiber, K.H.; O’Leary, M.N.; Kennedy, B.K. The mTOR Pathway and Aging. In *The Handbook of the Biology of Aging*; Academic Press: Cambridge, MA, USA, 2016; pp. 55–81. [CrossRef]

245. Gabriel, D.; Gordon, L.B.; Djabali, K. Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Syndrome Cellular Phenotype. *PLoS ONE* 2016, 11, e0168988. [CrossRef]

246. Jiang, T.; Yu, J.-T.; Zhu, X.-C.; Zhang, Q.-Q.; Cao, L.; Wang, H.-F.; Tan, M.-S.; Gao, Q.; Qin, H.; Zhang, Y.-D.; et al. Temsirolimus attenuates tauopathy in vivo by targeting tau hyperphosphorylation and autophagic clearance. *Neuropharmacology* 2014, 85, 121–130. [CrossRef]

247. Jiang, T.; Yu, J.-T.; Zhu, X.-C.; Tan, M.S.; Wang, H.F.; Cao, L.; Zhang, Q.Q.; Shi, J.Q.; Gao, L.; Qin, H.; et al. Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer’s disease. *Pharmacol. Res.* 2014, 81, 54–63. [CrossRef]
271. Knop, F.K.; Konings, E.; Timmers, S.; Schrauwen, P.; Holst, J.J.; Blaak, E.E. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet. Med. 2013, 30, 1214–1218. [CrossRef]

272. Kennedy, D.O.; Wightman, E.L.; Reay, J.L.; Lietz, G.; Okello, E.J.; Wilde, A.; Haskell, C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010, 91, 1590–1597. [CrossRef] [PubMed]

273. Brown, V.A.; Patel, K.R.; Viskaduraki, M.; Crowell, J.A.; Booth, T.D.; Vasilillin, G.; Sen, A.; Schinas, A.M.; Piccirilli, G.; et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis. Cancer Res. 2010, 70, 9003–9011. [CrossRef] [PubMed]

274. Guo, X.; Kesimer, M.; Tolun, G.; Zheng, X.; Xu, Q.; Lu, J.; Sheehan, J.K.; Griffith, J.D.; Li, X. The nad(+)–dependent protein deacetylase activity of SIRT1 is regulated by its oligomeric status. Sci. Rep. 2012, 2, 640. [CrossRef] [PubMed]

275. Alobaji, A.O.; Adedara, A.O.; Adie, M.A.; Vicente-Crespo, M.; Farombi, E.O. Resveratrol prolongs lifespan and improves 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced oxidative damage and behavioural deficits in Drosophila melanogaster. Biochem. Biophys. Res. Commun. 2018, 503, 1042–1048. [CrossRef] [PubMed]

276. Bass, T.M.; Weinkove, D.; Houthoofd, K.; Gems, D.; Partridge, L. Effect of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech. Ageing Dev. 2007, 128, 546–552. [CrossRef] [PubMed]

277. Rascón, B.; Hubbard, B.P.; Sinclair, D.A.; Amdam, G.V. The lifespan extension effects of resveratrol are conserved in the honey bee and may be driven by a mechanism related to caloric restriction. Aging 2012, 4, 499–508. [CrossRef] [PubMed]

278. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; et al. Resveratrol improves health and survival of mice on high-calorie diet. Nature 2006, 444, 337–342. [CrossRef]

279. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.-L.; et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425, 191–196. [CrossRef]

280. Price, N.L.; Gomes, A.P.; Ling, A.J.; Duarte, F.V.; Martin-Montalvo, A.; North, B.J.; Agarwal, B.; Ye, L.; Ramadori, G.; Teodoro, J.S.; et al. SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function. Cell Metab. 2012, 15, 675–690. [CrossRef]

281. Hubbard, B.P.; Sinclair, D.A. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci. 2014, 35, 146–154. [CrossRef]

282. Cione, E.; La Torre, C.; Cannataro, R.; Caroleo, M.C.; Plastina, P.; Gallelli, L. Quercetin, Epigallocatechin Gallate, Curcumin, and Resveratrol: From Dietary Sources to Human MicroRNA Modulation. Molecules 2019, 25, 63. [CrossRef] [PubMed]

283. Medina-Aguilar, R.; Marchat, L.A.; Aréchaga-Ocampo, E.; Gariglio, P.; Mena, J.G.; Sepulveda, N.V.; Castillo, M.M.; López-Camarillo, C. Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells. Oncol. Rep. 2016, 35, 3696–3704. [CrossRef] [PubMed]

284. Arablou, T.; Delbandi, A.; Khodaverdi, S.; Arefi, S.; Kolahdouz-Mohammadi, R.; Heidari, S.; Mohammadi, T.; Aryaeian, N. Resveratrol reduces the expression of insulin-like growth factor-I and hepatocyte growth factor growth factor genes in stromal cells of women with endometriosis compared with nonendometriotic women. Oncol. Rep. 2016, 35, 1044–1054. [CrossRef] [PubMed]

285. Pallauf, K.; Chin, D.; Günther, I; Birringer, M.; Lüersen, K.; Schultheiß, G.; Vieten, S.; Krauß, J.; Bracher, F.; Danylec, N.; et al. Resveratrol, lunularin and dihydroresveratrol do not act as caloric restriction mimetics when administered intraperitoneally in mice. Sci. Rep. 2019, 9, 1–12. [CrossRef]

286. Günther, I; Rimbach, G.; Mack, C.I.; Weinert, C.H.; Danylec, N.; Lüersen, K.; Birringer, M.; Bracher, F.; Soukup, S.T.; Kulling, S.E.; et al. The Putative Caloric Restriction Mimetic Resveratrol has Moderate Impact on Insulin Sensitivity, Body Composition, and the Metabolome in Mice. Mol. Nutr. Food Res. 2020, 64, 1901116. [CrossRef]

287. Zhou, J.; Liao, Z.; Jia, J.; Chen, J.-L.; Xiao, Q. The effects of resveratrol feeding and exercise training on the skeletal muscle function and transcriptome of aged rats. PeerJ 2019, 7, e7199. [CrossRef]
288. Dey, A.; Guha, P.; Chattopadhyay, S.; Bandopadhyay, S.K. Biphasic activity of resveratrol on indomethacin-induced gastric ulcers. *Biochem. Biophys. Res. Commun.* 2009, 381, 90–95. [CrossRef]

289. Shaito, A.; Posadino, A.M.; Younes, N.; Hasan, H.; Halabi, S.; Alhababi, D.; Al-Mohannadi, A.; Abdel-Rahman, W.M.; Eid, A.H.; Nasrallah, G.K.; et al. Potential Adverse Effects of Resveratrol: A Literature Review. *Int. J. Mol. Sci.* 2020, 21, 2084. [CrossRef]

290. Ito, S.; Fujiki, Y.; Matsui, N.; Ojika, M.; Wakamatsu, K. Tyrosinase-catalyzed oxidation of resveratrol produces a highly reactive ortho-quinone: Implications for melanocyte toxicity. *Pigment Cell Melanoma Res.* 2017, 32, 766–776. [CrossRef]

291. Bolton, J.L.; Dunlap, T. Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects. *Chem. Res. Toxicol.* 2017, 30, 13–37. [CrossRef]

292. Porquet, D.; Griñán-Ferré, C.; Ferrer, I.; Camins, A.; Sanfeliu, C.; Del Valle, J.; Pallás, M. Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer’s disease. *J. Alzheimers Dis.* 2014, 42, 1209–1220. [CrossRef] [PubMed]

293. Chen, Z.H.; Hurh, Y.J.; Na, H.K.; Kim, J.H.; Chun, Y.J.; Kim, D.H.; Kang, K.S.; Cho, M.H.; Surh, Y.J. Resveratrol inhibits tced-induced expression of cyp1a1 and cyp1b1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. *Carcinogenesis* 2004, 25, 2005–2013. [CrossRef] [PubMed]

294. Cauchy, F.; Mebarki, M.; Leporq, B.; Laouirem, S.; Albuquerque, M.; Lambert, S.; Bourgoin, P.; Soubrane, O.; Andrzejewski, S.; Gravel, S.-P.; Pollak, M.; St-Pierre, J. Metformin directly acts on mitochondria to alter cellular bioenergetics. *Cancer Metab.* 2014, 5, 1–11. [CrossRef] [PubMed]

295. Song, Y.M.; Lee, W.K.; Lee, Y.H.; Kang, E.S.; Cha, B.S.; Lee, B.W. Metformin restores parkin-mediated mitophagy, suppressed by cytosolic p53. *Int. J. Mol. Sci.* 2016, 17, 122. [CrossRef]

296. Rotermund, C.; Machetanz, G.; Fitzgerald, J.C. The Therapeutic Potential of Metformin in Neurodegenerative Diseases. *Front. Endocrinol.* 2018, 9, 400. [CrossRef] [PubMed]

297. Ren, H.; Shao, Y.; Wu, C.; Ma, X.; Lv, C.; Wang, Q. Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway. *Mol. Cell. Endocrinol.* 2020, 500, 110628. [CrossRef]

298. Shaito, A.; Posadino, A.M.; Younes, N.; Hasan, H.; Halabi, S.; Alhababi, D.; Al-Mohannadi, A.; Abdel-Rahman, W.M.; Eid, A.H.; Nasrallah, G.K.; et al. Potential Adverse Effects of Resveratrol: A Literature Review. *Int. J. Mol. Sci.* 2020, 21, 2084. [CrossRef]

299. Porquet, D.; Griñán-Ferré, C.; Ferrer, I.; Camins, A.; Sanfeliu, C.; Del Valle, J.; Pallás, M. Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer’s disease. *J. Alzheimers Dis.* 2014, 42, 1209–1220. [CrossRef] [PubMed]

300. De Santi, M.; Baldelli, G.; Diotallevi, A.; Galluzzi, L.; Schiavano, G.F.; Brandi, G. Metformin prevents cell tumorigenesis through autophagy-related cell death. *Sci. Rep.* 2019, 9, 1–11. [CrossRef] [PubMed]

301. Andrzejewski, S.; Gravel, S.-P.; Pollak, M.; St-Pierre, J. Metformin directly acts on mitochondria to alter cellular bioenergetics. *Cancer Metab.* 2014, 5, 1–11. [CrossRef] [PubMed]

302. Al-Zaidan, L.; Abu El Ruz, R.; Malki, A. Screening Novel Molecular Targets of Metformin in Breast Cancer by Proteomic Approach. *Front. Public Health* 2017, 5, 277. [CrossRef]

303. De Santì, M.; Baldelli, G.; Diotallevi, A.; Galluzzi, L.; Schiavano, G.F.; Brandi, G. Metformin prevents cell tumorigenesis through autophagy-related cell death. *Sci. Rep.* 2019, 9, 1–11. [CrossRef] [PubMed]

304. De Santì, M.; Baldelli, G.; Diotallevi, A.; Galluzzi, L.; Schiavano, G.F.; Brandi, G. Metformin prevents cell tumorigenesis through autophagy-related cell death. *Sci. Rep.* 2019, 9, 1–11. [CrossRef] [PubMed]

305. Fitzgerald, J.C.; Zimprich, A.; Berrio, D.A.C.; Schindler, K.M.; Maurer, B.; Schulte, C.; Bus, C.; Hauser, A.-K.; Kübler, M.; Lewin, R.; et al. Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson’s disease. *Brain J. Neurol.* 2017, 140, 2444–2459. [CrossRef] [PubMed]

306. Patil, S.; Jain, P.; Ghumatkar, P.; Tambe, R.; Sathaye, S. Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice. *Neuroscience* 2014, 277, 747–754. [CrossRef] [PubMed]

307. Chen, J.; Ou, Y.; Li, Y.; Hu, S.; Shao, L.W.; Liu, Y. Metformin extends c.elegans lifespan through lysosomal pathway. *eLife* 2017, 6, 1–17. [CrossRef]
308. Jiralerspong, S.; Palla, S.L.; Giordano, S.H.; Meric-Bernstam, F.; Liedtke, C.; Barnett, C.M.; Hsu, L.; Hung, M.-C.; Hortobagyi, G.N.; Gonzalez-Angulo, A.M. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. *J. Clin. Oncol.* 2009, 27, 3297–3302. [CrossRef]

309. Wan, G.; Yu, X.; Chen, P.; Wang, X.; Pan, D.; Wang, X.; Li, L.; Cai, X.; Cao, F. Metformin therapy associated with survival benefit in lung cancer patients with diabetes. *Oncotarget* 2016, 7, 35437–35445. [CrossRef]

310. Sonnenblick, A.A.; Agbor-Tarh, D.D.; Bradbury, I.I.; Di Cosimo, S.; Azim, H.H.A.; Fumagalli, D.; Sarp, S.S.; Wolff, A.A.C.A.; Andersson, M.M.; Kroep, J.J.; et al. Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. *J. Clin. Oncol.* 2017, 35, 1421–1429. [CrossRef]

311. Kulkarni, A.S.; Brutsaert, E.F.; Anghel, V.; Zhang, K.; Bloomgarden, N.; Pollak, M.; Mar, J.C.; Hawkins, M.; Crandall, J.P.; Barzilai, N. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. *Aging Cell* 2018, 17, e12723. [CrossRef]

312. Song, J.; Jiang, G.; Zhang, J.; Guo, J.; Li, Z.; Hao, K.; Liu, L.; Cheng, Z.; Tong, X.; Dai, F. Metformin prolongs lifespan through remodeling the energy distribution strategy in silkworm, Bombyx mori. *Aging* 2019, 11, 240–248. [CrossRef] [PubMed]

313. Qin, X.; Du, D.; Chen, Q.; Wu, M.; Wu, T.; Wen, J.; Jin, Y.; Zhang, J.; Wang, S. Metformin prevents murine ovarian aging. *Aging* 2019, 11, 3785–3794. [CrossRef] [PubMed]

314. Martin-Montalvo, A.; Mercken, E.M.; Mitchell, S.J.; Palacios, H.H.; Mote, P.L.; Scheibye-Knudsen, M.; Gomes, A.P.; Ward, T.M.; Minor, R.K.; Blouin, M.-J.; et al. Metformin improves healthspan and lifespan in mice. *Nat. Commun.* 2013, 4, 2192. [CrossRef] [PubMed]

315. Cabreiro, F.; Au, C.; Leung, K.-Y.; Vergara-Irigaray, N.; Cochemé, H.M.; Noori, T.; Weinkove, D.; Schuster, E.; Greene, N.D.; Gems, D. Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism. *Cell* 2013, 153, 228–239. [CrossRef]

316. Gillespie, Z.E.; Wang, C.; Vadon, F.; Yu, T.Y.; Aussió, J.; Kusalik, A.; Eskiw, C.H. Metformin induces the AP-1 transcription factor network in normal dermal fibroblasts. *Sci. Rep.* 2019, 9, 5369. [CrossRef]

317. Saisho, Y. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. *Endocrine Metab. Immune Disord. Drug Targets* 2015, 15, 196–205. [CrossRef]

318. Ustinova, M.; Silamikelis, I.; Kalnina, I.; Ansone, L.; Rovite, V.; Radovica-Spalvina, I.; Fridmanis, D.; Aladyeva, J.; Konrade, I.; et al. Metformin strongly affects transcriptome of peripheral blood cells in healthy individuals. *PLoS ONE* 2019, 14, e0224835. [CrossRef]

319. Cree-Green, M.; Bergman, B.C.; Cengiz, E.; Fox, L.A.; Hannon, T.S.; Miller, K.M.; Nathan, B.; Pyle, L.; Kahn, D.; Tansey, M.; et al. Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes. *J. Clin. Endocrinol. Metab.* 2019, 104, 3265–3278. [CrossRef]

320. Yang, X.; Kord-Varkaneh, H.; Talaei, S.; Clark, C.C.; Zanghelini, F.; Tan, S.C.; Zarezadeh, M.; Mousavi, S.M.; Rahmani, J.; Zhang, Y. The influence of metformin on IGF-1 levels in humans: A systematic review and meta-analysis. *Pharmacol. Res.* 2020, 151, 104588. [CrossRef]